WO2002011768A1 - Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels - Google Patents

Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels Download PDF

Info

Publication number
WO2002011768A1
WO2002011768A1 PCT/EP2001/009007 EP0109007W WO0211768A1 WO 2002011768 A1 WO2002011768 A1 WO 2002011768A1 EP 0109007 W EP0109007 W EP 0109007W WO 0211768 A1 WO0211768 A1 WO 0211768A1
Authority
WO
WIPO (PCT)
Prior art keywords
gel
pharmaceutical composition
transdermal
composition according
testosterone
Prior art date
Application number
PCT/EP2001/009007
Other languages
French (fr)
Inventor
Dario Carrara
Gabriel Porto
Jorge Rodriguez
Original Assignee
Antares Pharma Ipl Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60127134T priority Critical patent/DE60127134T2/en
Priority to ES01960619T priority patent/ES2283425T3/en
Application filed by Antares Pharma Ipl Ag filed Critical Antares Pharma Ipl Ag
Priority to JP2002517102A priority patent/JP2004505931A/en
Priority to NZ524423A priority patent/NZ524423A/en
Priority to KR1020037001526A priority patent/KR100856523B1/en
Priority to AU8206401A priority patent/AU8206401A/en
Priority to US10/343,570 priority patent/US7214381B2/en
Priority to CA2418135A priority patent/CA2418135C/en
Priority to EP01960619A priority patent/EP1307232B1/en
Priority to AU2001282064A priority patent/AU2001282064B2/en
Publication of WO2002011768A1 publication Critical patent/WO2002011768A1/en
Priority to US10/798,161 priority patent/US7198801B2/en
Priority to US11/634,005 priority patent/US7404965B2/en
Priority to US11/693,988 priority patent/US7470433B2/en
Priority to US11/755,923 priority patent/US20070225379A1/en
Priority to US12/614,216 priority patent/US8980290B2/en
Priority to US13/044,447 priority patent/US20110195114A1/en
Priority to US13/106,715 priority patent/US20110245215A1/en
Priority to US13/566,900 priority patent/US8652491B2/en
Priority to US14/489,252 priority patent/US20150005337A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention relates to a novel composition for transdermal administration of different active compounds or a mixture thereof.
  • the invention reveals a pharmaceutical formulation with good cosmetic properties and low irritation potential, useful for the systemic treatment of diverse diseases by transdermal or transmucosal route.
  • Said chemicals are: fatty alcohols such as lauryl alcohol, n-decanol, oleyl alcohol, etc. and diethylene glycol monoethyl ether in a ternary vehicle composite consisting of ethanol, propylene glycol and water.
  • transdermal or transmucosal route for delivery of drugs provides many advantages, and transdermal or transmucosal systems for delivering a wide variety of drugs are described in U.S. patents number 5,785,991 ; 4,764,381; 4,956,171; 4,863,970; 5,453,279; 4,883,660; 5,719,197 or EP patent application number 0 271 983; 0 267 617; 0 261 429; 0 526 561; as an example, some of which are mentioned hereinafter.
  • a major drawback of this therapy is the limitation of the amount of drug that can be transported across the skin, in many cases, drugs which would appear to be ideal candidates for transdermal delivery are found to have such low permeability through intact skin that they cannot be delivered in therapeutically effective amounts from transdermal devices.
  • This limitation is due to several factors. Since the skin is a protective barrier by nature, the rates of transport of most compounds through the skin is quite slow. It is generally accepted that a surface of patch beyond 50-100 sqcm would result in difficulty of application. Therefore the application of a transdermal semisolid dosage form such as a gel, cream, ointment, liquid, etc., augments the patient's compliance and the surface of application can be extended.
  • a permeation enhancer or a combination thereof should have the ability to enhance the permeability of the skin for the drug, should be non-toxic, non-irritant and non-sensitizing on repeated exposure. It is often difficult to predict which compounds will work as permeation enhancers and which permeation enhancers will work for particular drugs.
  • a compound that enhances the permeability of one drug or a family of drugs may not necessarily enhance the permeability of another drug or family of drugs. That is also concluded after careful analysis of the scientific literature relating to this specific topics, such as "Transdermal Therapeutic
  • EPA 0 279 977 describes a transdermal device for administering progesterone and an estradiol ester alone or in combination, utilizing a polymer matrix which has the drug(s) with a penetration enhancer such as sucrose monococoate, glycerol monooleate, sucrose monolaurate, glycerol monolaureate, etc.
  • EPA 0 367 431 discloses that aliphatic alcohols such as isopropyl alcohol and isobutyl alcohol that are commonly used in topical transdermal formulation, thus, enhance the rate of transdermal delivery of steroid drugs.
  • WO 90/11 064 discloses a skin penetration enhancer composition for fransdermally administered pharmacologically active agents.
  • the composition contains diethylene glycol monoethyl or monomefhyl ether in addition to an ester component such as propylene glycol monolaurate, methyl laurate or the like.
  • US 5,785,991 discloses a composition, device and method for transdermal administration of an active agent using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, glycerol monolaurate.
  • US 4,764,381 discloses pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-efhyl-l,3 hexanediol alone or in combination with oleic acid.
  • US 4,863,970 discloses penetration-enhancing pharmaceutical compositions for topical transepidermal and percutaneous application which are non-irritating to the skin and describes a binary system of oleic acid or alcohol and a lower alcohol.
  • US 5,453,279 describes an enhancing transdermal absorption composition useful in transdermal absorption of progestins including progesterone and optionally an estrogen for contraceptive or HRT.
  • the enhancing composition comprise a combination of a lower alkyl ester of a polycarboxylic acid, an aliphatic monohydroxy alcohol and an aliphatic diol.
  • EP 0 526 561 Bl relates to the use of chemical penetration enhancers to enhance the transdermal delivery of medicaments through the skin, said chemical enhancers are alcohols.
  • None of the above mentioned inventions or publications report a study of lauryl alcohol together with diethylene glycol monoethyl ether in a ternary vehicle composite in a semisolid dosage form, designed to administer fransdermally or through the mucosal membrane the group of active agents mentioned in the present invention. None of the above mentioned inventions or publications describe an adequate transdermal or transmucosal formulation to deliver therapeutic plasma levels of different types of active compounds, as it is disclosed in the present invention.
  • One object of the present invention is to obtain a transdermal formulation that could deliver, at controlled rates, an active compound or a mixture thereof, combined with appropriate permeation enhancers.
  • penetration enhancers to administer a drug (s) by transdermal route.
  • W. R. Pfister in its chapter on “Transdermal and Dermal Therapeutic Systems: Current Status” in “Transdermal and Topical Drug Delivery Systems", Interpharm Press Inc., Buffalo Grove Illinois,
  • transdermal permeability is mainly influenced by both physicochemical properties of the permeants and by the interaction of the permeants with the enhancers. Therefore a given enhancer could prove to be very adequate for a drug and simultaneously would not increase the permeability of the other compound. This is well illustrated by Chien, in its chapter on “Developmental Concepts and Practice in Transdermal Therapeutic Systems” in Transdermal Controlled Systemic Medications, Marcel Dekker Inc., New York, 1987, pages 25-81, who states that a penetration enhancer increases the permeation of different compound to different degree.
  • Figure 1 represents an apparatus "Hanson P/N 57- VC (vertical diffusion cell) 3, is schematically represented wherein:
  • sample tube 12 sample probe from microette
  • Typical cell dimensions are: orifice 15 mm, volume 7 ml.
  • Figure 2 represents Graphic I relevant to the data from Table II.
  • Figure 3 represents Graphic II relevant to the data from Table TV
  • Figure 4 represents Graphic III relevant to the data from Table V
  • Figure 5 represents Graphic IV relevant to the data from Table VI
  • Figure 6 represents Graphic V relevant to the data from Table VII
  • Figure 7 represents Graphic VI relevant to the data from Table VIII
  • Figure 8 represents Graphic VII relevant to the data from Table X
  • Figure 9 represents Graphic VIII relevant to the data from Table IX
  • Figure 10 represents Graphic IX relevant to the data from Table XII
  • Figure 11 represents Graphic X relevant to the data from Table XIV
  • Figure 12 represents Graphic XI relevant to the data from Table XV
  • Figure 13 represents Graphic XII relevant to the data from Table XVI
  • Figure 14 represents Graphic XIII relevant to the data from Table XVIII
  • Figure 15 represents Graphic XIV relevant to the data from Table XX
  • Figure 16 represents Graphic XV relevant to the data from Table XXII
  • Figure 17 represents Graphic XVI relevant to the data from Table XXIII
  • Figure 18 represents Graphic XVII relevant to the data from Table XXIV
  • composition of the present invention relates to a penetration enhancing system that can be utilized in many types of products for topical or transdermal application, that include, but are not limited to, solutions, creams, lotions, sprays, ointment, gels, aerosols and patch devices.
  • this invention utilizes a novel combination of fatty alcohol (lauryl alcohol) and diethylene glycol monoalkyl ether (diethylene glycol monoethyl ether), and the combined effect is a significant and surprising improvement over use of lauryl alcohol or diethylene glycol monoethyl ether alone.
  • the present invention relates to a composition for topical application having penetration-enhancing properties, the composition comprising an active or a mixture thereof; and a penetration enhancing system that comprises lauryl alcohol and preferably also diethylene glycol monoalkyl ether in combination with a complex ternary vehicle comprising purified water, a C ⁇ -C 4 alcohol and a glycol.
  • the composition further comprises a gelling agent and a neutralizing agent when necessary.
  • the gelling agent is a carbomer (Carbopol ) which is a polyacrylic acid and/or a polyoxyethylene polyoxypropylene copolymer and the neutralizing agent is an amine like triethanolamine or tromethamine.
  • Preservatives, flavor agents, saborizants, sweeteners any other solubilizants can be added as well.
  • the enhancing composition herein presented has proven to effectively enhance delivery and absorption of physiologically active substances through the skin and mucosa. That was properly demonstrated by first carrying out in vitro studies to evaluate its applicability to a determined active drug(s) and then to further confirm its effectiveness in in vivo studies in human volunteers.
  • the penetration enhancing system of the present invention can also be used for mucosal delivery.
  • the present invention relates to a method for administering topically or systemically different active substance(s).
  • a compound that enhances the permeability of one drug or a family of drugs may not necessarily enhance the permeability of another drug or family of drugs.
  • An objective of this invention is to provide a formulation, which shows adequate transdermal penetration enhancement effect for different therapeutical compounds classified in different groups.
  • the main objective of this invention is to provide a semisolid dosage form, which shows adequate and effective transdermal penetration enhancement for different active drugs.
  • a skin permeation enhancer composition comprising of a first component that is a saturated fatty alcohol or fatty acid given by the formula CH 3 -(CH 2 ) n -CH 2 OH or CH 3 -(CH 2 ) n -
  • n is an integer from 8 to 22, preferably 8 to 12, most preferably 10 or an unsaturated fatty alcohol or fatty acid given by the formula
  • n is an integer from 8 to 22; and preferably also a second component that is a monoalkyl ether of diethylene glycol, preferably diethylene glycol monoethyl ether or diethylene glycol monomethyl ether, in a vehicle or carrier composition, integrated by an C ⁇ -C 4 alkanol, preferably ethanol; a polyalcohol, preferably propylene glycol and purified water.
  • the composition may also comprise additional components such as gelling agents, pH regulators, preservatives, flavor agents, saborizants, sweeteners, stabilizers, antioxidants, other solubilizants and the like.
  • the transdermal delivery system of the present invention comprises:
  • active agents or a mixture thereof.
  • the term '"drug” or “active drug” or “active agents” or “pharmaceutical active drug” as used to describe the principal active ingredient of the device intends a biologically active compound or mixture compounds that has a therapeutic, prophylactic or other beneficial pharmacological and/or physiological effect on the wearer of the device.
  • types of drugs are: a) Hormones: estrogens such as 17 beta -Estradiol, Estradiol, Estradiol Benzoate,
  • Estradiol 17 beta -Cypionate Estriol, Estrone, Ethynil Estradiol, Mestranol,
  • Fluoxymesterone, Testosterone, Testosterone derivatives such as: 17- Methyltestosterone, Testosterone 17 beta -Cypionate, Testosterone Enanthate, Testosterone Nicotinate, Testosterone Pheynylacetate, Testosterone Propionate, etc.
  • Sedatives and anxyolitics for instance Benzodiazepine derivatives such as Alprazolam, Bromazepam, Flutazolam, Ketazolam, Lorazepam, Prazepam, etc;
  • Amides such as Butoctamide, Diethylbromoacetamide, Ibrotamide, Isovaleryl Diethylamide, Niaprazine, Tricetamide, Trimetozine, Zolpidem, Zopiclone, etc; Arylpiperazines such as Buspirone, etc.
  • Antihypothyroids such as Levothyroxine, Thyroid, Thyroxine, etc.
  • Antihypertensives for instance Benzothiadiazine Derivatives such as Captopril,
  • Blockers such as Arylalkylamines such as Bepridil, Ditiazem, Fendiline, Gallopamil, Terodiline, Verapamil; Dihydropyridine Derivatives such as Felodipine, Isradipine, Nicardipine, Nifedipine, Nilvadipine, Nimodipine, Nisoldipine, Nitrendipine, Piperazine; Derivatives such as Flunarisine; others such as Perhexiline Calcium Regulator such as Calcifediol, Calcitonin, Calcitriol, Clodronic Acid,
  • Arylalkylamines such as Bepridil, Ditiazem, Fendiline, Gallopamil, Terodiline, Verapamil
  • Dihydropyridine Derivatives such as Felodipine, Isradipine, Nicardipine, Nifedipine, Nilvadipine, Nimodipine, Nisoldipine, Nitrend
  • Dihydrotachysterol Edihydrotachysterol, Elcatonin, Etidronic Acid, Ipriflavone, Pamidronic Acid, Parathyroid Hormone, Teriparatide Acetate, etc.
  • the present invention could be applied to other groups of pharmaceutical active agents for instance for alpha -Adrenergic Agonists such as Budralazine, Clonidine, Epinephrine, Fenoxazoline, Naphazoline, Phenylephrine,
  • Phenylpropanolamine, beta -Adrenergic Agonists such as Formoterol, Methoxyphenamine, alpha -Adrenergic Blockers such as Doxazosin, Prazosin, Terazosin, Trimazosin, Yohimbine, beta -Adrenergic Blockers such as Atenolol, Bisoprolol, Carteolol, Carvedilol, Metoprolol, Nadolol, Penbutolol, Analgesics (Narcotics) such as Bupreno hine, Dihydromorphine, Metazocine, Methadone, Morphine, Morphine Derivatives, Nicomorphine, Oxymorphone, etc.; Nerve Agents for smoking cessation i.e. such as Nicotine, Nicotine Citrate and Nicotine Tartrate,
  • Antineoplastic Agents such as 5-Fluorouracil, etc; Analgesics (Non-Narcotics), Analgesic and Anti-Inflamatory Agents; Anesthetics; Antiandrogens; Antianginals; Anticholinergics; Anticonvulsants; Antidepressants; Antiepileptics; Antiestrogen such as Tamoxifen, 4-OH Tamoxifen; Antihistaminics; Antiparkinsonians; Bronchodilators; Diuretics; Glucocorticoids; Muscle Relaxants; Narcotic
  • the active agent is intended to mean a single active agent or a combination of more than one active agent.
  • the amount of the systemically and/or topically active agent included in the formulation is subject to the degree to which penetration enhancement is achieved.
  • the active agents are: Testosterone presented in the compositions in about 0.05 to about 10.0 %>w/w; preferably from about 0.1 to about 5.0 %w/w and more preferably 0.6 to 4.0 %w/w.
  • Levonorgestrel presented in the compositions in about 0.02 to about 3.0 %>w/w; preferably from about 0.04 to 0.5 %w/w and more preferably 0.06 to 0.12 %w/w.
  • Progesterone presented in the compositions in about 0.1 to about 10.0 %w/w; preferably from about 0.1 to 5.0
  • Alprazolam presented in the compositions in about 0.02 to about 6.0 %w/w; preferably from about 0.1 to 3.0 %w/w and more preferably 0.5 to 2.0 %w/w.
  • L-Thyroxine presented in the compositions in about 0.02 to about 4.0 %>w/w; preferably from about 0.04 to 2.0 %w/w and more preferably 0.2 to 1.0 %w/w.
  • Amlodipine or Amlodipine Besylate presented in the compositions in about 0.05 to about 5.0 %w/w; preferably from about 0.2 to 3.0 %w/w and more preferably 0.5 to 2.0 %w/w. 2.
  • a ternary vehicle composite comprised of a C 2 -C alkanol such as ethanol, isopropanol, n-propanol, butanol, preferably ethanol; a polyalcohol or glycol such as propylene glycol, butylene glycol, hexylene glycol, ethylene glycol, preferably propylene glycol and finally purified water.
  • the compositions in accordance with the present invention contain an alcohol, preferably ethanol, in an amount of about 5.0 to about 75.0 %w/w; preferably from about 15.0 % to about 65.0 %w/w and more preferably 20.0 to 55.0 %w/w.
  • compositions of the present invention comprises a glycol, preferably propylene glycol in about 0.5 to about 50.0 %>w/w; preferably from about 3.0 to 20.0 %w/w and more preferably 4.0 to 10.0 %w/w. 3.
  • a permeation enhancer system comprising of a first component that is a saturated fatty alcohol or fatty acid given by the formula CH 3 -(CH 2 ) n -CH 2 OH or CH 3 -(CH ) n -CH 2 COOH respectively, in which n is an integer from 8 to 22, preferably 8 to 12, most preferably 10 or an unsaturated fatty alcohol or fatty acid given by the formula CH 3 -(C n H 2 ( n - X ))-OH or CH 3 -(C n H 2(n .
  • compositions in accordance with the present invention contain a fatty alcohol, preferably lauryl alcohol or dodecanol in about 0.1 to about 20.0 %w/w on the whole composition; preferably form about 0.4 to 10.0 %w/w and more preferably 0.2 to 3.0 %>w/w; and, optionally, a diethylene glycol monoalkyl ether in amount up to 40.0 %ow/w; preferably from about 0.2 to 25.0
  • %w/w and more preferably 2.0 to 8.0 %w/w.
  • a gelling agent or viscosant e.g. carbomer, carboxyethylene or polyacrylic acid such as Carbopol 980 or 940 NF, 981 or 941 NF, 1382 or 1342 NF, 5984 or 934 NF, ETD 2020, 2050, 934P NF, 971P NF, 974P NF, Noveon AA-1 USP, etc; cellulose derivatives such as ethylcellulose, hydroxypropylmethylcellulose (HPMC), efhyl- hydroxyethylcellulose (EHEC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC) (Klucel different grades), hydroxyethylcellulose (HEC) (Natrosol grades), HPMCP 55, Methocel grades, etc; natural gums such as arabic, xanthan, guar gums, alginates, etc; polyvinylpyrrolidone derivatives such as
  • Lutrol F grades and Carbopol grades were preferred.
  • Suitable gelling agents to apply the present invention include, but are not limited to, Carbopol 980 NF, Lutrol F 127, Lutrol F 68 and Noveon AA-1 USP.
  • the gelling agent is present from about 0.2 to about 30.0
  • a pH regulator normally a neutralizant agent, which can optionally have crosslinking function e.g. a ternary amine such as triethanolamine, fromethamine, tetrahydroxypropylethylendiamine, etc; NaOH solution, etc.
  • the pH regulator is present in the formulations in about 0.05 to about 2.0 %>w/w.
  • ingredients can optionally be included, for example, preservatives and/or antioxidants such as buthylhydroxytoluene, buthylhydroxyanisole, ethylenediaminetetraacetic acid and its sodium salts, DL-alfa tocoferol, antioxidant complexes, etc; co-solvents or solubilizers such as glycerol, polyethylene glycols, polyethylene glycols derivatives, polyethyleneglycol 660 hydroxystearate (Solutol)
  • formulations in which the present invention could be added assume any of a variety of dosage forms. Examples are gels, creams, lotions, sprays, ointments, aerosols, patches, buccal and sublingual tablets, suppositories, vaginal dosage forms and different passive or/and active transdermal devices for absorption through the skin or mucosa.
  • the present invention relates to a method for administering topically or systemically active agent(s), comprising: 1. An active agent(s); 2. A ternary vehicle composite (composed by a C1-C4 alkanol, a glycol and water); 3. A penetration enhancers combination (fatty alcohol or acid and diethylene glycol monoethyl ether); 4. A gelling agent and 5. A pH regulator.
  • transdermal formulation comprising different group of drugs as active agents; lauryl alcohol and diethylene glycol monoethyl ether as penetration enhancers, in a ternary vehicle composite comprised of ethanol, propylene glycol and purified water, using a polymer or copolymer of acrylic acid, preferably a carbomer as gelling forming, provides therapeutically effective serum concentration of each active agent throughout at least a 24 hours period.
  • a bioavailability study of the above mentioned formulations were carried out in human beings volunteers.
  • the main aim followed by the present invention is to rapidly create a high concentration of the drug(s) in contact with the skin or mucosa attained by the careful combination of permeation enhancers and vehicles.
  • the fatty alcohol is mainly distributed to the stratum corneum because of its lipophilicity and interacts with the stratum corneum lipids.
  • the diethylene glycol monoethyl ether dissolves both an hydrophilic and a lipophilic active agents therein and facilitates the penetration of the active agents to the skin.
  • An alkanol such as ethanol, also has a function to increase the stratum corneum liquid fluidity or a function to extract lipids from the stratum corneum.
  • Propylene glycol acts as a cosolvent of the drugs hence increase the solubility of the active agent in the formulation and solvated the intracellular keratin of the stratum corneum and thus enhanced drug mobility and skin hydration.
  • Water serves to augment the solubility of a hydrophilic active agent in the formulation and accelerates the release of lipophilic active agent from a formulation.
  • a polymer or copolymer of acrylic acid, such as a carbomer acts as a gelling forming and facilitates the release of lipophilic active agent and penetration enhancer.
  • a tertiary amine, such as triethanolamine or trolamine, has the function to thicken and neutralize the system.
  • the active agents and the compounds which enhances their penetration rate are dissolved in a ternary vehicle composite integrated by an alkanol having 1-4 C atoms, preferably ethanol; a polyalcohol, preferably propylene glycol and purified water.
  • This invention relates to a novel composition for transdermal or transmucosal application to humans in an optimized dosage form and methods for providing therefrom a controlled and sustained administration of different group of drugs.
  • Poration enhancement or “permeation enhancement” as used herein relates to an increase in the permeability of skin to a pharmacologically active agent, i.e., so as to increase the rate at which the drug permeates through the skin and enters the bloodstream.
  • the enhanced permeation effected through the use of such enhancers, and in particular, through the use of the enhancer composition of the present invention, can be observed by measuring the rate of diffusion of drug through animal or human skin using a diffusion cell apparatus as described in the examples herein.
  • an “effective” or an “adequate” permeation enhancer as used herein means a permeation enhancer that will provide the desired increase in skin permeability and correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.
  • transdermal delivery applicants intend to include both transdermal (or “percutaneous”) and transmucosal administration, i.e., delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream.
  • Carriers or “vehicles” as used herein refer to carrier materials suitable for transdermal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non toxic and which does not interact with other components of the composition in a deleterious manner.
  • suitable vehicles for use herein include water, alcohols, polyalcohols, and glycols.
  • pharmacologically active agent or “drug” as used herein is meant any chemical material or compound suitable for transdermal or transmucosal administration which induces a desired systemic effect.
  • controlled is meant reduce or minimize peak and valley normally present in some routes of administration of a pharmacologically active agent.
  • sustained is meant extended maintenance of steady state plasma levels.
  • therapeutically effective amount of a pharmacologically active agent is meant sufficient amount of a compound to provide the desired therapeutic effect, avoiding high or low plasmatic levels, obtaining, therefore, plasmatic levels of active within the therapeutic window.
  • aqueous phase disersion of the carbomer in water
  • an alcoholic phase solution containing the active drugs, Lauryl Alcohol, Diethylene glycol monoethyl ether (Transcutol P), and Ethyl Alcohol, or some of them according to the formulation
  • the Propylene Glycol and Disodium EDTA were added to the aqueous phase after the carbomer dispersion.
  • aqueous and alcoholic phases were mixed and Triethanolamine was added to neutralize the carbomer and form the gel.
  • the exemption was gels containing Hydroxypropyl Cellulose, which were manufactured by dispersing the Hydroxypropyl Cellulose in the hydroalcoholic solution containing the rest of the components.
  • the solutions were prepared by dissolving the active drugs in the rest of the excipients and shaking up to total dissolution.
  • the active substances included in the different formulations used in the examples or referred to in tables and graphics are defined through the following list of initials:
  • EELNg Ethynil Estradiol + Levonorgestrel gel
  • Alg Alprazolam gel
  • T4s L-Thyroxine solution
  • TEg Testosterone + Estradiol gel
  • Ams Amlodipine solution
  • AmBss Amlodipine Besylate solution
  • Example 4 (Te014-0n
  • Example 7 (Tg020-01 A gel composed by Testosterone 0.30 % w/w, Lauryl Alcohol 2.00 % w/w,
  • Diethylene glycol monoethyl ether (Transcutol) 4.96 % w/w, Propylene Glycol 5.95 % w/w, Ethyl Alcohol 42.64 % w/w, Distilled Water 42.52 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described.
  • Example 8 (TgQ21-01 >
  • Example 9 Tg030-01 1
  • Example 12 fTgQ37-0n A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 2.00 % ⁇ w/w, Propylene Glycol 5.99 % w/w, Ethyl Alcohol 49.00 % w/w, Distilled Water 40.19 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described.
  • Example 13 (Tg038-0n A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 1.99 % w/w, Oleyl alcohol 1.50 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w,
  • Diethylene glycol monoethyl ether (Transcutol P) 5.01 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 44.24 % w/w, Distilled Water 40.93 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described.
  • a gel composed by Testosterone 2.50 % w/w, Lauryl Alcohol 1.00 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.02 %> w/w, Propylene Glycol
  • Example 16fTEg002-01 A gel composed by Testosterone 0.183 % w/w, 17 ⁇ -Estradiol 0.060 % w/w, Lauryl
  • Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described.
  • Example 18fTEgQ06-0n A gel composed by Testosterone 0.20 % w/w, 17B-Estradiol 0.06 % w/w, Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w,
  • Disodium EDTA 0.06 %> w/w was prepared according to the manufacturing technique herein described.
  • Example 22fEELNg002-0n A gel composed by Ethynil Estradiol 0.090 % w/w, Levonorgestrel 0.090 % w/w,
  • Example 26 (Alg007-01 ) A gel composed by Alprazolam 1.80 % w/w, Lauryl Alcohol 2.03 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.03 % w/w, Propylene Glycol 6.00
  • Example 27 (Alg008-01 ) A gel composed by Alprazolam 0.50 % w/w, Lauryl Alcohol 1.99 % w/w,
  • Diethylene glycol monoethyl ether (Transcutol P) 21.94 % w/w, Propylene Glycol 11.04 % w/w, Solutol 11.01 % w/w, Lutrol F127 7.00 % w/w, Lutrol F68 3.00 % w/w, Distilled Water 42.23 % w/w, Noveon AA-1 1.01 % w/w, Triethanolamine 0.30 % w/w was prepared according to the manufacturing technique herein described.
  • Example 3 l( 4s005-02
  • a gel composed by 17 ⁇ -Estradiol 0.060 % w/w, Norethindrone Acetate 1.20 % w/w,
  • Example 38 (Ams002-0n A solution composed by Amlodipine base 1.00 %> w/w, Lauryl Alcohol 2.06 % w/w,
  • Example 39 (AmBss002-0n A solution composed by Amlodipine Besylate 1.00 % w/w, Lauryl Alcohol 2.07 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.15 % w/w, Propylene
  • Glycol 91.78 % w/w was prepared according to the manufacturing technique herein described.
  • Example 40 (Pg001- ⁇ n A gel composed by Progesterone 1.00 % w/w, Lauryl Alcohol 2.00 % w/w,
  • a gel composed by Progesterone 2.00 % w/w, Lauryl Alcohol 2.01 % w/w,
  • Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w, Propylene Glycol 6.02 % w/w, Ethyl Alcohol 44.18 % w/w, Distilled Water 39.21 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.39 % w/w, was prepared according to the manufacturing technique herein described.
  • Example 42(LNEg011-01) A gel composed by Levonorgestrel 0.05 % w/w, 17 ⁇ -Estradiol 0.100 % w/w, Lauryl
  • Example 44 A gel composed by Levonorgestrel 0.030 % w/w, 17 ⁇ -Estradiol 0.061 % w/w, Lauryl Alcohol 2.01 %> w/w, Diethylene glycol monoethyl ether (Transcutol) 4.98 % w/w, Propylene Glycol 5.95 % w/w, Ethyl Alcohol 45.30 %> w/w, Distilled Water 40.03 % w/w, Carbomer (Carbopol 980 NF) 1.22 % w/w, Triethanolamine 0.36 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described.
  • Example 45 NEgQ12-01)
  • a gel composed by Levonorgestrel 0.091 % w/w, 17 ⁇ -Estradiol 0.100 % w/w,
  • Propylene Glycol 97.95 % w/w was prepared according to the manufacturing technique herein described.
  • Example 50f Alps003) A solution composed by Alprazolam 0.98 %> w/w, Oleic Acid 1.59 % w/w, Propylene
  • Glycol 97.44 %> w/w was prepared according to the manufacturing technique herein described.
  • Propylene Glycol 97.99 %> w/w was prepared according to the manufacturing technique herein described.
  • the receptor chamber was maintained at 35°C and the studies were conducted under occlusive or non-occlusive conditions and at 600 rpm of stirring speed. At given time points, samples were withdrawn from the receptor solution and the receptor chamber was immediately refilled with fresh solution. All samples were analyzed using a high performance liquid chromatography (HPLC) method.
  • HPLC high performance liquid chromatography
  • Transdermal flux (mcg/sqcm/h) was determined from the steady-state slope of the plot of the cumulative amount of the drug(s) permeated through the skin versus time. After steady-state had been established, the linear portion of the plot was used to calculate the flux from the slope.
  • the objective of the study was to evaluate the bioavailability of E2 and LN from an optimized Combi Gel ® - LN, in 6 healthy postmenopausal female volunteers.
  • Example 1 contains Lauryl alcohol and Diethylene glycol monoethyl ether as permeation enhancers system.
  • Example 2 contains Diethylene glycol monoethyl ether alone.
  • Example 3 contains Lauryl alcohol alone
  • Example 9 contains no permeation enhancers
  • the objective of the study was to evaluate the bioavailabihty of Testosterone from an optimized Combi GelTM TESTOSTERONE in 8 hypogonadal volunteers.
  • n.a. means not available
  • Testosterone 0,60 %w/w and Estradiol 0,060 %w/w (Example 17) was selected for its evaluation in a preliminary bioavailabihty study.
  • the objective of the study was to evaluate the bioavailability of Testosterone and
  • Transdermal - Volunteers A total of 6 healthy postmenopausal women were selected. All of them completed the study and were submitted to analysis.
  • Venous blood samples were collected immediately prior to (basal value) and at 24, 48, 72, 96, 120, 144, 146, 150, 156, 168 h after the first application of Combi Gel TestoE2.
  • E2 serum levels were assayed using immunofluorescence and Testosterone serum levels were assayed using radioimmunoassay.
  • Combi Gel is considered feasible, since a prediction of in vivo fluxes for both actives when it was compared with Combi Gel NETA + E2 (example 34) concluded to be very close to the recommended daily doses. That means, about 50 ⁇ g/day for Ethynil Estradiol and 200- 300 ⁇ g/day for Levonorgestrel. Combi GelTM Progesterone
  • Pro-Gest ® is a commercially available cream containing 30 mg/g of original natural Progesterone. Pro-Gest ® has been claimed as a product to help maintain balance in woman's lives and keep them feeling in harmony with their bodies. There are publications of two independent clinical studies showing the results of the effect of Pro-Gest ® percutaneous progesterone body cream on postmenopausal women
  • LA contains Why Acid OA: contains Oleic Acid
  • OAL contains Oleyl Alcohol
  • LAOL contains Lauryl Alcohol It is clearly advisable the effect of the addition of the permeation enhancers to a solution containing Alprazolam as active agent. With the extremely low cumulative amount value obtained with the solution without containing permeation enhancers, one can expect very low rate of permeability for this active drug, nevertheless, the addition of the permeation enhancers clearly increase many times the flux of active drug permeated.
  • - Treatment A single daily dose of 2.0 g of Combi Gel® Alprazolam was applied on the shoulders (one gram on a 400 cm2 area of each shoulder) during 7 days.
  • - Biological sampling schedule Venous blood samples were collected immediately prior to (basal value) and at 1, 3, 6, 12, 24, 72, 73, 75, 78, 84, 96, 144, 145, 147, 150, 156 y 168 h after the first application of gel.
  • Sustained-Release Formulation Furthermore, utilizing the invention means herein claimed, it is possible to achieve sustained plasmatic levels avoiding "peaks and valleys" with only one daily application of Combi Gel Alprazolam.
  • Alprazolam Buccal Gel (containing 1,0 mg of Alprazolam). Blood samples were taken at the time points indicated in the table and graphic. Alprazolam was analyzed by HPLC.
  • Group D ANTIHYPERTENSIVES/CALCIUM CHANNEL BLOCKERS

Abstract

The present invention refers to a pharmaceutical composition suitable for the transdermal or transmucosal administration of one or more active agents, in form of a gel or a solution, comprising as a permeation enhancers a combination of: a) saturated fatty alcohol of formula CH3-(CH2)n-CH2OH or saturated fatty acid CH3-(CH2)n-CH2COOH wherein n is an integer number 8 22, preferably 8 12, most preferably 10, or unsaturated fatty alcohol or fatty acid of formula: CH3(CnH2(n-1))-OH or CH3(CnH2(n-1))-COOH wherein n is an integer number 8 22, b) a ternary vehicle or carrier consisting of a C1 C4 alkanol, a polyalcohol in particular propylenglycol and water, c) optionally also a monoalkylether of diethylenglycol.

Description

NOVEL COMPOSITION FOR TRANSDERMAL AND/OR
TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS FIELD OF THE INVENTION The present invention relates to a novel composition for transdermal administration of different active compounds or a mixture thereof. The invention reveals a pharmaceutical formulation with good cosmetic properties and low irritation potential, useful for the systemic treatment of diverse diseases by transdermal or transmucosal route. A formulation that administers the active drug (s), at a permeation rate that would ensure therapeutically effective systemic concentration, containing defined amounts of chemicals that minimize the barrier characteristics of the most uppermost layer of the epidermis and provide sustained permeation rate. Said chemicals are: fatty alcohols such as lauryl alcohol, n-decanol, oleyl alcohol, etc. and diethylene glycol monoethyl ether in a ternary vehicle composite consisting of ethanol, propylene glycol and water.
BACKGROUND OF THE INVENTION
It is well known that many drugs taken orally, are destroyed on the first pass through the liver. It is also well known that when many drugs are taken orally, their rate of absorption into the body is not constant. In view of such difficulties, a number of different drug delivery systems have been developed.
The transdermal or transmucosal route for delivery of drugs provides many advantages, and transdermal or transmucosal systems for delivering a wide variety of drugs are described in U.S. patents number 5,785,991 ; 4,764,381; 4,956,171; 4,863,970; 5,453,279; 4,883,660; 5,719,197 or EP patent application number 0 271 983; 0 267 617; 0 261 429; 0 526 561; as an example, some of which are mentioned hereinafter.
A major drawback of this therapy however, is the limitation of the amount of drug that can be transported across the skin, in many cases, drugs which would appear to be ideal candidates for transdermal delivery are found to have such low permeability through intact skin that they cannot be delivered in therapeutically effective amounts from transdermal devices. This limitation is due to several factors. Since the skin is a protective barrier by nature, the rates of transport of most compounds through the skin is quite slow. It is generally accepted that a surface of patch beyond 50-100 sqcm would result in difficulty of application. Therefore the application of a transdermal semisolid dosage form such as a gel, cream, ointment, liquid, etc., augments the patient's compliance and the surface of application can be extended.
In order to increase skin permeability so that drugs can be delivered in therapeutically effective amounts at therapeutically effective rates, it has been proposed different systems or devices or mechanisms one of which is deliver the drug (s) in presence of permeation enhancers. Usually, using penetration enhancing compounds, processes or devices to increase drug penetration solve this problem.
Various systems were suggested for this purpose, as described in different patents such as U.S. patents number 5,785,991; 4,764,381; 4,956,171; 4,863,970; 5,453,279; 4,883,660; 5,719,197 or W.O. patents number 97/29735; 98/17316 or in the literature "Pharmaceutical Skin Penetration Enhancement", J. Hadgraft, Marcel Dekker, Inc. 1993; "Percutaneous Absorption", R. Bronaugh, H. Maibach, Marcel
Dekker, Inc. 1989, etc.
To be accepted, a permeation enhancer or a combination thereof should have the ability to enhance the permeability of the skin for the drug, should be non-toxic, non-irritant and non-sensitizing on repeated exposure. It is often difficult to predict which compounds will work as permeation enhancers and which permeation enhancers will work for particular drugs. In transdermal drug delivery applications, a compound that enhances the permeability of one drug or a family of drugs may not necessarily enhance the permeability of another drug or family of drugs. That is also concluded after careful analysis of the scientific literature relating to this specific topics, such as "Transdermal Therapeutic
Systemic Medications, Marcel Dekker Inc., New York, 1989" (see table on page 3).
Therefore, the usefulness of a particular compound(s) or mixture thereof as a permeation enhancer must be carefully analyzed and demonstrated by empirical work. EPA 0 279 977 describes a transdermal device for administering progesterone and an estradiol ester alone or in combination, utilizing a polymer matrix which has the drug(s) with a penetration enhancer such as sucrose monococoate, glycerol monooleate, sucrose monolaurate, glycerol monolaureate, etc.
EPA 0 367 431 discloses that aliphatic alcohols such as isopropyl alcohol and isobutyl alcohol that are commonly used in topical transdermal formulation, thus, enhance the rate of transdermal delivery of steroid drugs.
WO 90/11 064 discloses a skin penetration enhancer composition for fransdermally administered pharmacologically active agents. The composition contains diethylene glycol monoethyl or monomefhyl ether in addition to an ester component such as propylene glycol monolaurate, methyl laurate or the like. US 5,785,991 discloses a composition, device and method for transdermal administration of an active agent using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, glycerol monolaurate.
US 4,764,381 discloses pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-efhyl-l,3 hexanediol alone or in combination with oleic acid.
US 4,863,970 discloses penetration-enhancing pharmaceutical compositions for topical transepidermal and percutaneous application which are non-irritating to the skin and describes a binary system of oleic acid or alcohol and a lower alcohol. US 5,453,279 describes an enhancing transdermal absorption composition useful in transdermal absorption of progestins including progesterone and optionally an estrogen for contraceptive or HRT. The enhancing composition comprise a combination of a lower alkyl ester of a polycarboxylic acid, an aliphatic monohydroxy alcohol and an aliphatic diol. EP 0 526 561 Bl relates to the use of chemical penetration enhancers to enhance the transdermal delivery of medicaments through the skin, said chemical enhancers are alcohols.
None of the above mentioned inventions or publications report a study of lauryl alcohol together with diethylene glycol monoethyl ether in a ternary vehicle composite in a semisolid dosage form, designed to administer fransdermally or through the mucosal membrane the group of active agents mentioned in the present invention. None of the above mentioned inventions or publications describe an adequate transdermal or transmucosal formulation to deliver therapeutic plasma levels of different types of active compounds, as it is disclosed in the present invention.
One object of the present invention is to obtain a transdermal formulation that could deliver, at controlled rates, an active compound or a mixture thereof, combined with appropriate permeation enhancers. As it is well described in the literature of the art, there is not obviousness regarding the use of penetration enhancers to administer a drug (s) by transdermal route. As it is mentioned by W. R. Pfister in its chapter on "Transdermal and Dermal Therapeutic Systems: Current Status" in "Transdermal and Topical Drug Delivery Systems", Interpharm Press Inc., Buffalo Grove Illinois,
1997, pages 33-112, no general guidelines exist that will ensure success in selecting an appropriate enhancer for a specific drug to be delivered from a transdermal device (Hsieh 1994). The science of optimizing topical formulations is not predictive from one drug to another and permeation enhancers can produce a wide range of enhancement factors across drugs having different physicochemical properties.
Rather, this is a process that requires extensive experimental work.
It is also important to mention that transdermal permeability is mainly influenced by both physicochemical properties of the permeants and by the interaction of the permeants with the enhancers. Therefore a given enhancer could prove to be very adequate for a drug and simultaneously would not increase the permeability of the other compound. This is well illustrated by Chien, in its chapter on "Developmental Concepts and Practice in Transdermal Therapeutic Systems" in Transdermal Controlled Systemic Medications, Marcel Dekker Inc., New York, 1987, pages 25-81, who states that a penetration enhancer increases the permeation of different compound to different degree.
There has not been known an enhancer or combination thereof which shows the transdermal penetration enhancement effect for any active agent or drug. As an example we can quote results of this author as wherein below indicated:
Figure imgf000007_0001
Additionally, another argument in favor of our position is sustained when the results reported by Chien are analyzed. He published the dependence of the enhancement factor for the skin permeation of progesterone on the alkyl chain length of saturated fatty acid in "Transdermal Controlled Systemic Medications". He found the major enhancement effect using caproic acid (C8), however the same author discloses in US patent 5,145,682 that the better enhancer for estradiol is decanoic acid (CIO). These results lead us to attain the same conclusion of Chien in "Transdermal Controlled Systemic Medications", Marcel Dekker, New York 1987, pages 25-81, that concludes that the efficacy of skin penetration enhancer for a specific active agent, is function of the type, concentration and, how the penetration enhancer release from the devices.
The prior art presented herein clearly prove that at least for some compounds, as shown in the present patent application, there is no such an universal penetration enhancer composition and the adequate permeation rate across the skin can be achieved only by testing different types of compounds at different concentrations. Although prior art was useful for the theoretical approach, the results herein disclosed emerged from the careful investigation of multiple variables. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 represents an apparatus "Hanson P/N 57- VC (vertical diffusion cell) 3, is schematically represented wherein:
I = cell receptor 2 = donor chamber (dosage area)
3 = top plate
4 = dosage water
5 = clamp
6 = membrane 7 = water jacket
8 = sample point
9 = stirring helix
10 = magnetic stirrer
II = sample tube 12 = sample probe from microette
13 = cell level line
14 = media replace tube
Typical cell dimensions are: orifice 15 mm, volume 7 ml. Figure 2 represents Graphic I relevant to the data from Table II. Figure 3 represents Graphic II relevant to the data from Table TV
Figure 4 represents Graphic III relevant to the data from Table V Figure 5 represents Graphic IV relevant to the data from Table VI Figure 6 represents Graphic V relevant to the data from Table VII Figure 7 represents Graphic VI relevant to the data from Table VIII Figure 8 represents Graphic VII relevant to the data from Table X
Figure 9 represents Graphic VIII relevant to the data from Table IX Figure 10 represents Graphic IX relevant to the data from Table XII Figure 11 represents Graphic X relevant to the data from Table XIV Figure 12 represents Graphic XI relevant to the data from Table XV Figure 13 represents Graphic XII relevant to the data from Table XVI
Figure 14 represents Graphic XIII relevant to the data from Table XVIII Figure 15 represents Graphic XIV relevant to the data from Table XX Figure 16 represents Graphic XV relevant to the data from Table XXII Figure 17 represents Graphic XVI relevant to the data from Table XXIII Figure 18 represents Graphic XVII relevant to the data from Table XXIV Figure 19 represents Graphic XVIII relevant to the data from Table XXV Figure 20 represents Graphic XIX relevant to the data from Table XXVI for
Alprazolam pill and from Table XXVII for Alprazolam gel Figure 21 represents Graphic XX relevant to the data from Table XXIX Figure 22 represents Graphic XXI relevant to the data from Table XXX, Examples 37 and 39 Figure 23 represents Graphic XXII relevant to the data from Table XXX, Examples
36 and 38 SUMMARY OF THE INVENTION
The composition of the present invention relates to a penetration enhancing system that can be utilized in many types of products for topical or transdermal application, that include, but are not limited to, solutions, creams, lotions, sprays, ointment, gels, aerosols and patch devices.
While it is known in the art to combine permeation enhancers, this invention utilizes a novel combination of fatty alcohol (lauryl alcohol) and diethylene glycol monoalkyl ether (diethylene glycol monoethyl ether), and the combined effect is a significant and surprising improvement over use of lauryl alcohol or diethylene glycol monoethyl ether alone.
The present invention relates to a composition for topical application having penetration-enhancing properties, the composition comprising an active or a mixture thereof; and a penetration enhancing system that comprises lauryl alcohol and preferably also diethylene glycol monoalkyl ether in combination with a complex ternary vehicle comprising purified water, a Cι-C4 alcohol and a glycol. The composition further comprises a gelling agent and a neutralizing agent when necessary. In preferred embodiments, the gelling agent is a carbomer (Carbopol ) which is a polyacrylic acid and/or a polyoxyethylene polyoxypropylene copolymer and the neutralizing agent is an amine like triethanolamine or tromethamine.
Preservatives, flavor agents, saborizants, sweeteners any other solubilizants can be added as well. The enhancing composition herein presented has proven to effectively enhance delivery and absorption of physiologically active substances through the skin and mucosa. That was properly demonstrated by first carrying out in vitro studies to evaluate its applicability to a determined active drug(s) and then to further confirm its effectiveness in in vivo studies in human volunteers. The penetration enhancing system of the present invention can also be used for mucosal delivery.
Hence, it has been surprisingly discovered that it is possible to achieve a therapeutically effective, sustained and controlled penetration rate of diverse active substances into the skin with the aid of the inventive means. It has been discovered surprisingly that the formulation discloses herein, exerts higher permeation rate when is compared with a formulation without containing the invention.
It has been surprisingly discovered also that by utilizing lauryl alcohol and diethylene glycol monoethyl ether (Transcutol®P) as enhancing composition for the invention herein disclosed, an adequate penetration enhancement factor and a sustained flux of the active agent is attained, thereafter reflected in achieving therapeutic effective, controlled and sustained levels of the active drugs by only once-a-day application of the formulation.
In another aspect, the present invention relates to a method for administering topically or systemically different active substance(s).
DETAILED DESCRIPTION OF THE INVENTION
It is often difficult to predict which compounds will work as permeation enhancers and which permeation enhancers will work for particular drugs. In transdermal drug delivery applications, a compound that enhances the permeability of one drug or a family of drugs may not necessarily enhance the permeability of another drug or family of drugs.
Therefore, the usefulness of a particular compound(s) or mixture thereof as a permeation enhancer must be carefully analyzed.
An objective of this invention is to provide a formulation, which shows adequate transdermal penetration enhancement effect for different therapeutical compounds classified in different groups. The main objective of this invention is to provide a semisolid dosage form, which shows adequate and effective transdermal penetration enhancement for different active drugs.
Accordingly, it is an object of the present invention to provide a skin permeation enhancer composition comprising of a first component that is a saturated fatty alcohol or fatty acid given by the formula CH3-(CH2)n-CH2OH or CH3-(CH2)n-
CH2COOH respectively, in which n is an integer from 8 to 22, preferably 8 to 12, most preferably 10 or an unsaturated fatty alcohol or fatty acid given by the formula
CH3-(C nH2(n-X))-OH or CH -(C nH2(n.x))-COOH respectively in which n is an integer from 8 to 22; and preferably also a second component that is a monoalkyl ether of diethylene glycol, preferably diethylene glycol monoethyl ether or diethylene glycol monomethyl ether, in a vehicle or carrier composition, integrated by an Cι-C4 alkanol, preferably ethanol; a polyalcohol, preferably propylene glycol and purified water. The composition may also comprise additional components such as gelling agents, pH regulators, preservatives, flavor agents, saborizants, sweeteners, stabilizers, antioxidants, other solubilizants and the like.
The transdermal delivery system of the present invention comprises:
1. One or more active agents, or a mixture thereof. The term '"drug" or "active drug" or "active agents" or "pharmaceutical active drug" as used to describe the principal active ingredient of the device intends a biologically active compound or mixture compounds that has a therapeutic, prophylactic or other beneficial pharmacological and/or physiological effect on the wearer of the device. Examples of types of drugs are: a) Hormones: estrogens such as 17 beta -Estradiol, Estradiol, Estradiol Benzoate,
Estradiol 17 beta -Cypionate, Estriol, Estrone, Ethynil Estradiol, Mestranol,
Moxestrol, Mytatrienediol, Polyestradiol Phosphate, Quinestradiol, Quinestrol, etc; progestogens such as Allylestrenol, Anagestone, Chlormadinone Acetate,
Delmadinone Acetate, Demegestone, Desogestrel, Dimethisterone, Dydrogesterone, Ethynilestrenol, Ethisterone, Ethynodiol, Ethynodiol Diacetate, Flurogestone
Acetate, Gestodene, Gestonorone Caproate, Haloprogesterone, 17-Hydroxy-16- methylene-progesterone, 17 alpha -Hydroxyprogesterone, 17 alpha Hydroxygesterone Caproate, Lynestrenol, Medrogestone, Medroxyprogesterone, Megestrol Acetate, Melengestrol, Norethindrone, Norethindrone Acetate, Norethynodrel, Norgesterone, Norgestimate, Norgestrel, Norgestrienone, 1 - Norprogesterone, Norvinisterone, Pentagestrone, Progesterone, Natural Progesterone, Promegestone, Quingestrone, Trengestone, etc; androgens such as
Fluoxymesterone, Testosterone, Testosterone derivatives such as: 17- Methyltestosterone, Testosterone 17 beta -Cypionate, Testosterone Enanthate, Testosterone Nicotinate, Testosterone Pheynylacetate, Testosterone Propionate, etc. b) Sedatives and anxyolitics for instance Benzodiazepine derivatives such as Alprazolam, Bromazepam, Flutazolam, Ketazolam, Lorazepam, Prazepam, etc;
Amides such as Butoctamide, Diethylbromoacetamide, Ibrotamide, Isovaleryl Diethylamide, Niaprazine, Tricetamide, Trimetozine, Zolpidem, Zopiclone, etc; Arylpiperazines such as Buspirone, etc. c) Antihypothyroids such as Levothyroxine, Thyroid, Thyroxine, etc. d) Antihypertensives for instance Benzothiadiazine Derivatives such as Captopril,
Cilazapril, Enalapril, Lisinopril, Perindopril, Ramipril; Guanidine Derivatives such as Guanethidine; Quinazoline Derivatives such as Alfuzosin; Reserpine Derivatives such as Reserpine, Sulfonamide Derivatives such as Furosemide; others such as Minoxidil, Amlodipine, Doxazosin Mesylate, Felodipine, Moxonidine, Nicardipine Hydrochloride, Nifedipine, Prazosin hydrochloride, etc and Calcium Channel
Blockers such as Arylalkylamines such as Bepridil, Ditiazem, Fendiline, Gallopamil, Terodiline, Verapamil; Dihydropyridine Derivatives such as Felodipine, Isradipine, Nicardipine, Nifedipine, Nilvadipine, Nimodipine, Nisoldipine, Nitrendipine, Piperazine; Derivatives such as Flunarisine; others such as Perhexiline Calcium Regulator such as Calcifediol, Calcitonin, Calcitriol, Clodronic Acid,
Dihydrotachysterol, Elcatonin, Etidronic Acid, Ipriflavone, Pamidronic Acid, Parathyroid Hormone, Teriparatide Acetate, etc.
The present invention could be applied to other groups of pharmaceutical active agents for instance for alpha -Adrenergic Agonists such as Budralazine, Clonidine, Epinephrine, Fenoxazoline, Naphazoline, Phenylephrine,
Phenylpropanolamine, beta -Adrenergic Agonists such as Formoterol, Methoxyphenamine, alpha -Adrenergic Blockers such as Doxazosin, Prazosin, Terazosin, Trimazosin, Yohimbine, beta -Adrenergic Blockers such as Atenolol, Bisoprolol, Carteolol, Carvedilol, Metoprolol, Nadolol, Penbutolol, Analgesics (Narcotics) such as Bupreno hine, Dihydromorphine, Metazocine, Methadone, Morphine, Morphine Derivatives, Nicomorphine, Oxymorphone, etc.; Nerve Agents for smoking cessation i.e. such as Nicotine, Nicotine Citrate and Nicotine Tartrate,
Antineoplastic Agents such as 5-Fluorouracil, etc; Analgesics (Non-Narcotics), Analgesic and Anti-Inflamatory Agents; Anesthetics; Antiandrogens; Antianginals; Anticholinergics; Anticonvulsants; Antidepressants; Antiepileptics; Antiestrogen such as Tamoxifen, 4-OH Tamoxifen; Antihistaminics; Antiparkinsonians; Bronchodilators; Diuretics; Glucocorticoids; Muscle Relaxants; Narcotic
Antagonists; etc.
It is to be understood herein that the active agent is intended to mean a single active agent or a combination of more than one active agent.
The amount of the systemically and/or topically active agent included in the formulation is subject to the degree to which penetration enhancement is achieved.
In the preferred embodiments, the active agents are: Testosterone presented in the compositions in about 0.05 to about 10.0 %>w/w; preferably from about 0.1 to about 5.0 %w/w and more preferably 0.6 to 4.0 %w/w. Estradiol presented in the compositions in about 0.02 to about 3.0 %w/w; preferably from about 0.04 to 2.0 %w/w and more preferably 0.06 to 0.12 %>w/w. Ethynil Estradiol presented in the compositions in about 0.02 to about 3.0 %>w/w; preferably from about 0.04 to 0.5 %w/w and more preferably 0.06 to 0.12 %w/w. Levonorgestrel presented in the compositions in about 0.02 to about 3.0 %>w/w; preferably from about 0.04 to 0.5 %w/w and more preferably 0.06 to 0.12 %w/w. Progesterone presented in the compositions in about 0.1 to about 10.0 %w/w; preferably from about 0.1 to 5.0
%w/w and more preferably 1.0 to 3.0 %w/w. Alprazolam presented in the compositions in about 0.02 to about 6.0 %w/w; preferably from about 0.1 to 3.0 %w/w and more preferably 0.5 to 2.0 %w/w. L-Thyroxine presented in the compositions in about 0.02 to about 4.0 %>w/w; preferably from about 0.04 to 2.0 %w/w and more preferably 0.2 to 1.0 %w/w. Amlodipine or Amlodipine Besylate presented in the compositions in about 0.05 to about 5.0 %w/w; preferably from about 0.2 to 3.0 %w/w and more preferably 0.5 to 2.0 %w/w. 2. A ternary vehicle composite comprised of a C2-C alkanol such as ethanol, isopropanol, n-propanol, butanol, preferably ethanol; a polyalcohol or glycol such as propylene glycol, butylene glycol, hexylene glycol, ethylene glycol, preferably propylene glycol and finally purified water. The compositions in accordance with the present invention contain an alcohol, preferably ethanol, in an amount of about 5.0 to about 75.0 %w/w; preferably from about 15.0 % to about 65.0 %w/w and more preferably 20.0 to 55.0 %w/w. In addition, the compositions of the present invention comprises a glycol, preferably propylene glycol in about 0.5 to about 50.0 %>w/w; preferably from about 3.0 to 20.0 %w/w and more preferably 4.0 to 10.0 %w/w. 3. A permeation enhancer system comprising of a first component that is a saturated fatty alcohol or fatty acid given by the formula CH3-(CH2)n-CH2OH or CH3-(CH )n-CH2COOH respectively, in which n is an integer from 8 to 22, preferably 8 to 12, most preferably 10 or an unsaturated fatty alcohol or fatty acid given by the formula CH3-(C nH2(n-X))-OH or CH3-(C nH2(n.X))-COOH respectively in which n is an integer from 8 to 22; and preferably also a second component that is a monoalkyl ether of diethylene glycol, preferably diethylene glycol monoethyl ether or diethylene glycol monomethyl. The compositions in accordance with the present invention contain a fatty alcohol, preferably lauryl alcohol or dodecanol in about 0.1 to about 20.0 %w/w on the whole composition; preferably form about 0.4 to 10.0 %w/w and more preferably 0.2 to 3.0 %>w/w; and, optionally, a diethylene glycol monoalkyl ether in amount up to 40.0 %ow/w; preferably from about 0.2 to 25.0
%w/w and more preferably 2.0 to 8.0 %w/w.
4. A gelling agent or viscosant, e.g. carbomer, carboxyethylene or polyacrylic acid such as Carbopol 980 or 940 NF, 981 or 941 NF, 1382 or 1342 NF, 5984 or 934 NF, ETD 2020, 2050, 934P NF, 971P NF, 974P NF, Noveon AA-1 USP, etc; cellulose derivatives such as ethylcellulose, hydroxypropylmethylcellulose (HPMC), efhyl- hydroxyethylcellulose (EHEC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC) (Klucel different grades), hydroxyethylcellulose (HEC) (Natrosol grades), HPMCP 55, Methocel grades, etc; natural gums such as arabic, xanthan, guar gums, alginates, etc; polyvinylpyrrolidone derivatives such as
Kollidon grades; polyoxyethylene polyoxypropylene copolymers such as Lutrol F grades 68, 127, etc; others like chitosan, polyvinyl alcohols, pectins, veegun grades, etc. In the present invention, Lutrol F grades and Carbopol grades were preferred. Those of the skill in the art should know of other gelling agents or viscosants that are suitable to practice the present invention. Suitable gelling agents to apply the present invention include, but are not limited to, Carbopol 980 NF, Lutrol F 127, Lutrol F 68 and Noveon AA-1 USP. The gelling agent is present from about 0.2 to about 30.0
%w/w depending on the type of polymer.
5. A pH regulator, normally a neutralizant agent, which can optionally have crosslinking function e.g. a ternary amine such as triethanolamine, fromethamine, tetrahydroxypropylethylendiamine, etc; NaOH solution, etc. The pH regulator is present in the formulations in about 0.05 to about 2.0 %>w/w.
6. Other ingredients can optionally be included, for example, preservatives and/or antioxidants such as buthylhydroxytoluene, buthylhydroxyanisole, ethylenediaminetetraacetic acid and its sodium salts, DL-alfa tocoferol, antioxidant complexes, etc; co-solvents or solubilizers such as glycerol, polyethylene glycols, polyethylene glycols derivatives, polyethyleneglycol 660 hydroxystearate (Solutol
HS15 from Basf), buthylene glycol, hexylene glycol, etc.
The formulations in which the present invention could be added, assume any of a variety of dosage forms. Examples are gels, creams, lotions, sprays, ointments, aerosols, patches, buccal and sublingual tablets, suppositories, vaginal dosage forms and different passive or/and active transdermal devices for absorption through the skin or mucosa.
As such, in another aspect, the present invention relates to a method for administering topically or systemically active agent(s), comprising: 1. An active agent(s); 2. A ternary vehicle composite (composed by a C1-C4 alkanol, a glycol and water); 3. A penetration enhancers combination (fatty alcohol or acid and diethylene glycol monoethyl ether); 4. A gelling agent and 5. A pH regulator.
It has been discovered that in a transdermal formulation comprising different group of drugs as active agents; lauryl alcohol and diethylene glycol monoethyl ether as penetration enhancers, in a ternary vehicle composite comprised of ethanol, propylene glycol and purified water, using a polymer or copolymer of acrylic acid, preferably a carbomer as gelling forming, provides therapeutically effective serum concentration of each active agent throughout at least a 24 hours period. As it is concluded when a bioavailability study of the above mentioned formulations were carried out in human beings volunteers.
The main aim followed by the present invention is to rapidly create a high concentration of the drug(s) in contact with the skin or mucosa attained by the careful combination of permeation enhancers and vehicles.
It is well known by the skills in the art that a sumatory or a sinergistic effect could be expected when two or more penetration enhancers are combined and included into a formulation. However, it is by no mean obvious to obtain an adequate penetration enhancement factor and a sustained flux of the active agent(s), achieving therapeutic effective levels, also controlled and sustained, by only one daily application of the formulation.
Accordingly, we can postulate that the behavior of our formulation was due to the addition of several phenomena especially on the stratum corneum.
Although the mechanism of such stratum corneum effect in the present invention is not fully clear by the scientific knowledge up to now, it can be understood as follows:
The fatty alcohol is mainly distributed to the stratum corneum because of its lipophilicity and interacts with the stratum corneum lipids.
The diethylene glycol monoethyl ether dissolves both an hydrophilic and a lipophilic active agents therein and facilitates the penetration of the active agents to the skin.
An alkanol, such as ethanol, also has a function to increase the stratum corneum liquid fluidity or a function to extract lipids from the stratum corneum.
Propylene glycol, a widespread pharmaceutical vehicle, acts as a cosolvent of the drugs hence increase the solubility of the active agent in the formulation and solvated the intracellular keratin of the stratum corneum and thus enhanced drug mobility and skin hydration.
Water serves to augment the solubility of a hydrophilic active agent in the formulation and accelerates the release of lipophilic active agent from a formulation. A polymer or copolymer of acrylic acid, such as a carbomer acts as a gelling forming and facilitates the release of lipophilic active agent and penetration enhancer. A tertiary amine, such as triethanolamine or trolamine, has the function to thicken and neutralize the system.
In the preferred embodiment of the present invention, the active agents and the compounds which enhances their penetration rate (lauryl alcohol and diethylene glycol monoethyl ether) are dissolved in a ternary vehicle composite integrated by an alkanol having 1-4 C atoms, preferably ethanol; a polyalcohol, preferably propylene glycol and purified water.
This invention relates to a novel composition for transdermal or transmucosal application to humans in an optimized dosage form and methods for providing therefrom a controlled and sustained administration of different group of drugs.
It is an object of the present invention to demonstrate its applicability not only for hormones but also for different group of pharmaceutical active agents. DEFINITION OF TERMS
"Penetration enhancement" or "permeation enhancement" as used herein relates to an increase in the permeability of skin to a pharmacologically active agent, i.e., so as to increase the rate at which the drug permeates through the skin and enters the bloodstream. The enhanced permeation effected through the use of such enhancers, and in particular, through the use of the enhancer composition of the present invention, can be observed by measuring the rate of diffusion of drug through animal or human skin using a diffusion cell apparatus as described in the examples herein.
An "effective" or an "adequate" permeation enhancer as used herein means a permeation enhancer that will provide the desired increase in skin permeability and correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.
By "transdermal" delivery, applicants intend to include both transdermal (or "percutaneous") and transmucosal administration, i.e., delivery by passage of a drug through the skin or mucosal tissue and into the bloodstream.
"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdermal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non toxic and which does not interact with other components of the composition in a deleterious manner. Examples of suitable vehicles for use herein include water, alcohols, polyalcohols, and glycols.
By the term "pharmacologically active agent" or "drug" as used herein is meant any chemical material or compound suitable for transdermal or transmucosal administration which induces a desired systemic effect.
By "controlled" is meant reduce or minimize peak and valley normally present in some routes of administration of a pharmacologically active agent.
By "sustained" is meant extended maintenance of steady state plasma levels. By "therapeutically effective" amount of a pharmacologically active agent is meant sufficient amount of a compound to provide the desired therapeutic effect, avoiding high or low plasmatic levels, obtaining, therefore, plasmatic levels of active within the therapeutic window. EXAMPLES
In order to further illustrate the present invention and the advantages thereof, the following specific examples are given. It being understood that the examples herein disclosed are intended only as illustrative and in nowise limitative.
All the examples were prepared basically as follow: an aqueous phase (dispersion of the carbomer in water) and an alcoholic phase (solution containing the active drugs, Lauryl Alcohol, Diethylene glycol monoethyl ether (Transcutol P), and Ethyl Alcohol, or some of them according to the formulation) were prepared separately. The Propylene Glycol and Disodium EDTA, were added to the aqueous phase after the carbomer dispersion. Finally, aqueous and alcoholic phases were mixed and Triethanolamine was added to neutralize the carbomer and form the gel. The exemption was gels containing Hydroxypropyl Cellulose, which were manufactured by dispersing the Hydroxypropyl Cellulose in the hydroalcoholic solution containing the rest of the components.
The solutions were prepared by dissolving the active drugs in the rest of the excipients and shaking up to total dissolution. The active substances included in the different formulations used in the examples or referred to in tables and graphics are defined through the following list of initials:
LNEg = Levonorgestrel + Estradiol gel Tg = Testosterone gel NEg = Norethindrone Acetate + Estradiol gel Pg = Progesterone gel
EELNg = Ethynil Estradiol + Levonorgestrel gel Alg = Alprazolam gel T4s = L-Thyroxine solution
T4g = L-Thyroxine gel Alps = Alprazolam solution
TEg = Testosterone + Estradiol gel Ams = Amlodipine solution AmBss = Amlodipine Besylate solution
Then, a numbering that represents different formulations with the same active drug (s) and same dosage form follows the initials. Example UTgO 17-041
A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 2.00 %> w/w, Diethylene glycol monoethyl ether (Transcutol P) 4.99 % w/w, Propylene Glycol
6.00 % w/w, Ethyl Alcohol 42.10 % w/w, Distilled Water 42.01 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.38 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 2(TgQ28-0n A gel composed by Testosterone 1.25 % w/w, Diethylene glycol monoethyl ether
(Transcutol P) 5.00 % w/w, Propylene Glycol 5.95 % w/w, Ethyl Alcohol 43.09 % w/w, Distilled Water 43.07 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.38 % w/w, Disodium EDTA 0.059 % w/w was prepared according to the manufacturing technique herein described. Example 3(Tg029-0n
A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 2.01 % w/w, Propylene Glycol 6.05 % w/w, Ethyl Alcohol 44.53 % w/w, Distilled Water 44.58 % w/w, Carbomer (Carbopol 980 NF) 1.23 % w/w, Triethanolamine 0.38 % w/w, Disodium EDTA 0.060 % w/w was prepared according to the manufacturing technique herein described. Example 4 (Te014-0n
A gel composed by Testosterone 2.50 % w/w, Lauryl Alcohol 2.02 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w, Propylene Glycol 6.02 % w/w, Ethyl Alcohol 45.57 % w/w, Distilled Water 37.29 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06
% w/w was prepared according to the manufacturing technique herein described. Example 5 (TgQl 8-01)
A gel composed by Testosterone 3.50 % w/w, Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.01 % w/w, Propylene Glycol 5.93 % w/w, Ethyl Alcohol 49.22 % w/w, Distilled Water 32.73 % w/w, Carbomer
(Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 6 (TgQl 9-θn A gel composed by Testosterone 0.60 % w/w, Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.02 % w/w, Propylene Glycol 5.94
% w/w, Ethyl Alcohol 42.41 % w/w, Distilled Water 42.41 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 7 (Tg020-01 A gel composed by Testosterone 0.30 % w/w, Lauryl Alcohol 2.00 % w/w,
Diethylene glycol monoethyl ether (Transcutol) 4.96 % w/w, Propylene Glycol 5.95 % w/w, Ethyl Alcohol 42.64 % w/w, Distilled Water 42.52 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 8 (TgQ21-01 >
A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 2.11 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.07 %> w/w, Propylene Glycol 6.01 % w/w, Ethyl Alcohol 46.19 % w/w, Distilled Water 37.78 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.33 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 9 (Tg030-01 1
A gel composed by Testosterone 1.25 % w/w, Propylene Glycol 5.95 % w/w, Ethyl Alcohol 45.46 % w/w, Distilled Water 45.67 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.39 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described.
Example 10 CTgQ35-02)
A gel composed by Testosterone 1.25 %> w/w, Lauryl Alcohol 2.02 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.01 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 46.25 % w/w, Distilled Water 37.91 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 11 rTe036-0n
A gel composed by Testosterone 2.50 % w/w, Lauryl Alcohol 2.00 %> w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00 %> w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 47.27 % w/w, Distilled Water 35.67 % w/w, Carbomer
(Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 12 fTgQ37-0n A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 2.00 %ι w/w, Propylene Glycol 5.99 % w/w, Ethyl Alcohol 49.00 % w/w, Distilled Water 40.19 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 13 (Tg038-0n A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 1.99 % w/w, Oleyl alcohol 1.50 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w,
Propylene Glycol 6.02 % w/w, Ethyl Alcohol 45.42 % w/w, Distilled Water 37.23 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 % w/w was prepared according to the manufacturing technique herein described. Example 14(Tg039-0D A gel composed by Testosterone 1.25 % w/w, Lauryl Alcohol 1.01 % w/w,
Diethylene glycol monoethyl ether (Transcutol P) 5.01 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 44.24 % w/w, Distilled Water 40.93 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 15fTg040-01 >
A gel composed by Testosterone 2.50 % w/w, Lauryl Alcohol 1.00 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.02 %> w/w, Propylene Glycol
5.99 % w/w, Ethyl Alcohol 46.02 % w/w, Distilled Water 37.92 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 16fTEg002-01) A gel composed by Testosterone 0.183 % w/w, 17β-Estradiol 0.060 % w/w, Lauryl
Alcohol 1.99 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.10 % w/w, Propylene Glycol 6.09 % w/w, Ethyl Alcohol 45.00 % w/w, Distilled Water 39.96 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06 %> w/w was prepared according to the manufacturing technique herein described.
Example 17(TEg005-θn
A gel composed by Testosterone 0.60 %> w/w, 17β-Estradiol 0.062 % w/w, Lauryl Alcohol 2.01 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.13 % w/w, Propylene Glycol 5.99 % w/w, Ethyl Alcohol 46.54 % w/w, Distilled Water 38.08 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.34 % w/w,
Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 18fTEgQ06-0n A gel composed by Testosterone 0.20 % w/w, 17B-Estradiol 0.06 % w/w, Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w,
Propylene Glycol 5.99 % w/w, Ethyl Alcohol 45.11 % w/w, Distilled Water 40.03 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 19(TEgQ08-θn
A gel composed by Testosterone 0.10 % w/w, 17β-Estradiol 0.06 % w/w, Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 45.16 % w/w, Distilled Water 40.07 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w,
Disodium EDTA 0.06 %> w/w was prepared according to the manufacturing technique herein described. Example 20(TEg009-0n
A gel composed by Testosterone 0.06 %> w/w, 17J3-Estradiol 0.058 %> w/w, Lauryl
Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w,
Propylene Glycol 6.00 % w/w, Ethyl Alcohol 45.18 % w/w, Distilled Water 40.09 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 21(EELNg001-0n
A gel composed by Ethynil Estradiol 0.060 % w/w, Levonorgestrel 0.089 % w/w, Lauryl Alcohol 1.99 % w/w, Diethylene glycol monoethyl ether (Transcutol) 4.98 % w/w, Propylene Glycol 6.13 % w/w, Ethyl Alcohol 45.20 % w/w, Distilled Water
39.94 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.34 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 22fEELNg002-0n A gel composed by Ethynil Estradiol 0.090 % w/w, Levonorgestrel 0.090 % w/w,
Lauryl Alcohol 2.02 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 45.13 % w/w, Distilled Water 40.06 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.34 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described.
Example 23f AlgQ04-02)
A gel composed by Alprazolam 1.00 % w/w, Lauryl Alcohol 2.08 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.01 % w/w, Propylene Glycol 6.12 % w/w, Ethyl Alcohol 44.65 % w/w, Distilled Water 39.58 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 % w/w was prepared according to the manufacturing technique herein described. Example 24(Alg005-0n
A gel composed by Alprazolam 1.80 % w/w, Lauryl Alcohol 1.99 %> w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 %> w/w, Propylene Glycol 6.11 % w/w, Ethyl Alcohol 44.32 % w/w, Distilled Water 39.25 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.34 % w/w was prepared according to the manufacturing technique herein described. Example 25(Alg006-01 )
A gel composed by Alprazolam 1.00 %> w/w, Oleic Acid 1.01 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w, Propylene Glycol 5.99 % w/w, Ethyl Alcohol 45.30 % w/w, Distilled Water 40.09 % w/w, Carbomer (Carbopol 980
NF) 1.26 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 26(Alg007-01 ) A gel composed by Alprazolam 1.80 % w/w, Lauryl Alcohol 2.03 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.03 % w/w, Propylene Glycol 6.00
% w/w, Ethyl Alcohol 46.81 % w/w, Distilled Water 36.77 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.36 % w/w was prepared according to the manufacturing technique herein described. Example 27(Alg008-01 ) A gel composed by Alprazolam 0.50 % w/w, Lauryl Alcohol 1.99 % w/w,
Diethylene glycol monoethyl ether (Transcutol P) 21.94 % w/w, Propylene Glycol 11.04 % w/w, Solutol 11.01 % w/w, Lutrol F127 7.00 % w/w, Lutrol F68 3.00 % w/w, Distilled Water 42.23 % w/w, Noveon AA-1 1.01 % w/w, Triethanolamine 0.30 % w/w was prepared according to the manufacturing technique herein described.
Example 28CAlg009-0n
A gel composed by Alprazolam 0.50 % w/w, Lauryl Alcohol 2.01 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 13.52 % w/w, Propylene Glycol 13.52 % w/w, Lutrol F127 6.99 % w/w, Lutrol F68 3.00 % w/w, Ethyl Alcohol 25.13 % w/w, Distilled Water 33.97 % w/w, Noveon AA-1 1.01 % w/w, Triethanolamine
0.30 % w/w was prepared according to the manufacturing technique herein described. Example 29(AlgO 10-01)
A gel composed by Alprazolam 0.50 % w/w, Propylene Glycol 15.16 %> w/w, Lutrol F127 7.00 % w/w, Lutrol F68 3.00 % w/w, Solutol HS15 15.17 % w/w, Distilled Water 57.90 % w/w, Noveon AA-1 0.99 % w/w, Triethanolamine 0.30 % w/w was prepared according to the manufacturing technique herein described.
Example 30(Alg016-01 )
A gel composed by Alprazolam 1.00 % w/w, Lauryl Alcohol 1.01 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.01 % w/w, Propylene Glycol 6.02 % w/w, Ethyl Alcohol 45.28 % w/w, Distilled Water 40.13 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w was prepared according to the manufacturing technique herein described. Example 3 l( 4s005-02
A clear solution composed by Na L-Thyroxine 0.40 % w/w, Lauryl Alcohol 1.97 %> w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.03 % w/w, Propylene Glycol 6.04 % w/w, Ethyl Alcohol 45.92 % w/w, Distilled Water 40.64 % w/w was prepared.
Example 32(T4s006-0n
A clear solution composed by Na L-Thyroxine 0.40 % w/w, Propylene Glycol 5.94 % w/w, Ethyl Alcohol 49.68 % w/w, Distilled Water 43.98 % w/w was prepared. Example 33(T4g005-01 )
A gel composed by Na L-Thyroxine 0.41 % w/w, Lauryl Alcohol 2.06 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.13 % w/w, Propylene Glycol 6.10 % w/w, Ethyl Alcohol 45.81 % w/w, Distilled Water 38.58 % w/w, Hydroxypropyl Cellulose 1.90 % w/w was prepared according to the manufacturing technique herein described.
Example 34fNEg098-05
A gel composed by 17β-Estradiol 0.060 % w/w, Norethindrone Acetate 1.20 % w/w, Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 44.57 %> w/w, Distilled Water 39.55 % w/w, Carbomer (Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.060 % w/w was prepared according to the manufacturing technique herein described. Example 35(NEgQ98-06
A gel composed by 17β-Estradiol 0.060 % w/w, Norethindrone Acetate 1.20 % w/w,
Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00
% w/w, Propylene Glycol 5.97 % w/w, Ethyl Alcohol 44.58 % w/w, Distilled Water 39.57 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.061 % w/w was prepared according to the manufacturing technique herein described.
Example 36f Ams001-0
A solution composed by Amlodipine base 1.00 %> w/w, Propylene Glycol 99.00 % w/w, was prepared according to the manufacturing technique herein described.
Example 37f AmBss001-0n
A solution composed by Amlodipine Besylate 1.00 % w/w, Propylene Glycol 99.00
% w/w, was prepared according to the manufacturing technique herein described.
Example 38(Ams002-0n A solution composed by Amlodipine base 1.00 %> w/w, Lauryl Alcohol 2.06 % w/w,
Diethylene glycol monoethyl ether (Transcutol P) 5.15 % w/w, Propylene Glycol
91.79 % w/w, was prepared according to the manufacturing technique herein described.
Example 39(AmBss002-0n A solution composed by Amlodipine Besylate 1.00 % w/w, Lauryl Alcohol 2.07 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.15 % w/w, Propylene
Glycol 91.78 % w/w, was prepared according to the manufacturing technique herein described.
Example 40(Pg001-θn A gel composed by Progesterone 1.00 % w/w, Lauryl Alcohol 2.00 % w/w,
Diethylene glycol monoethyl ether (Transcutol P) 5.02 % w/w, Propylene Glycol
6.01 % w/w, Ethyl Alcohol 44.78 % w/w, Distilled Water 39.77 % w/w, Carbomer
(Carbopol 980 NF) 1.21 % w/w, Triethanolamine 0.38 % w/w, was prepared according to the manufacturing technique herein described. Example 41(PgQ02-0n
A gel composed by Progesterone 2.00 % w/w, Lauryl Alcohol 2.01 % w/w,
Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w, Propylene Glycol 6.02 % w/w, Ethyl Alcohol 44.18 % w/w, Distilled Water 39.21 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.39 % w/w, was prepared according to the manufacturing technique herein described. Example 42(LNEg011-01) A gel composed by Levonorgestrel 0.05 % w/w, 17β-Estradiol 0.100 % w/w, Lauryl
Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol P) 5.00 % w/w, Propylene Glycol 6.01 % w/w, Ethyl Alcohol 45.18 % w/w, Distilled Water 40.05 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06 %> w/w was prepared according to the manufacturing technique herein described.
Example 43(LNEg002-01)
A gel composed by Levonorgestrel 0.090 % w/w, 17β-Estradiol 0.060 % w/w, Lauryl Alcohol 2.00 %> w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 45.18 % w/w, Distilled Water 40.07 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 44(LNEgQ03-01) A gel composed by Levonorgestrel 0.030 % w/w, 17β-Estradiol 0.061 % w/w, Lauryl Alcohol 2.01 %> w/w, Diethylene glycol monoethyl ether (Transcutol) 4.98 % w/w, Propylene Glycol 5.95 % w/w, Ethyl Alcohol 45.30 %> w/w, Distilled Water 40.03 % w/w, Carbomer (Carbopol 980 NF) 1.22 % w/w, Triethanolamine 0.36 % w/w, Disodium EDTA 0.06 % w/w was prepared according to the manufacturing technique herein described. Example 45 NEgQ12-01)
A gel composed by Levonorgestrel 0.090 % w/w, 17B-Estradiol 0.060 %> w/w, Lauryl Alcohol 2.02 %> w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 %> w/w, Propylene Glycol 6.01 % w/w, Ethyl Alcohol 45.20 %> w/w, Distilled Water 40.07 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.35 % w/w, was prepared according to the manufacturing technique herein described. Example 46(LNEg015-01)
A gel composed by Levonorgestrel 0.090 % w/w, 17β-Estradiol 0.061 %> w/w,
Propylene Glycol 6.03 % w/w, Ethyl Alcohol 48.82 % w/w, Distilled Water 43.42 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 %> w/w, was prepared according to the manufacturing technique herein described.
Example 47(LNEg013-01
A gel composed by Levonorgestrel 0.091 % w/w, 17β-Estradiol 0.100 % w/w,
Lauryl Alcohol 2.00 % w/w, Diethylene glycol monoethyl ether (Transcutol) 5.00 % w/w, Propylene Glycol 6.00 % w/w, Ethyl Alcohol 45.16 %> w/w, Distilled Water 40.07 % w/w, Carbomer (Carbopol 980 NF) 1.20 % w/w, Triethanolamine 0.36 % w/w, was prepared according to the manufacturing technique herein described.
Example 48(Alps001)
A solution composed by Alprazolam 1.09 % w/w, Propylene Glycol 98.91 %> w/w, was prepared according to the manufacturing technique herein described. Example 49( Alps002)
A solution composed by Alprazolam 1.06 % w/w, Laurie Acid 0.99 % w/w,
Propylene Glycol 97.95 % w/w, was prepared according to the manufacturing technique herein described.
Example 50f Alps003) A solution composed by Alprazolam 0.98 %> w/w, Oleic Acid 1.59 % w/w, Propylene
Glycol 97.44 %> w/w, was prepared according to the manufacturing technique herein described.
Example 5 If Alps004)
A solution composed by Alprazolam 1.02 %> w/w, Oleyl alcohol 1.11 % w/w, Propylene Glycol 97.89 % w/w, was prepared according to the manufacturing technique herein described.
Example 52f A1PS009)
A solution composed by Alprazolam 1.00 % w/w, lauryl alcohol 1.01 %> w/w,
Propylene Glycol 97.99 %> w/w, was prepared according to the manufacturing technique herein described.
IN VITRO DRUG PERMEATION STUDIES AND IN VIVO BIOAVAILABILITY
STUDIES In vitro drug permeation experiments through abdominal guinea pig skin were made using the diffusion chamber that is schematically shown in Figure 1 (Franz Vertical Diffusion Cell).
Female Guinea pigs, 8 to 16 months of age, were shaved on their abdominal skin 72 hours before sacrificing by cervical dislocation. Only animals that shown absence of lesions were used. A section of full thickness abdominal skin was surgically excised and mounted between the sections of a vertical diffusion cell having 1.77 sqcm of surface area, the epidermal facing up. A given amount of the transdermal devices exemplified previously (10, 25, 50 or 400 mg or 2, 3 ml) was applied over the epidermal layer whilst the dermal layer contact with the receptor solution: 2.0 %w/V polyoxyethylene 20 oleyl ether (Oleth 20), with or without PBS, pH 7,4. The receptor chamber was maintained at 35°C and the studies were conducted under occlusive or non-occlusive conditions and at 600 rpm of stirring speed. At given time points, samples were withdrawn from the receptor solution and the receptor chamber was immediately refilled with fresh solution. All samples were analyzed using a high performance liquid chromatography (HPLC) method.
Flux determination: Transdermal flux (mcg/sqcm/h) was determined from the steady-state slope of the plot of the cumulative amount of the drug(s) permeated through the skin versus time. After steady-state had been established, the linear portion of the plot was used to calculate the flux from the slope.
In order to demonstrate the improvements in the permeation performance applying the invention herein discloses, in vitro permeation studies of examples using the inventive means were compared with examples made without using this invention (without the addition of permeation enhancers). It was an objective to demonstrate the results obtained applying the invention herein disclose. In the in vitro drug permeation studies the examples using the invention herein claimed were compared with examples made without using this invention (without addition of the permeation enhancers). Also, with some active drugs of the exemplified groups, comparative in vitro permeation studies were done against a reference product, Combi Gel™ NETA (Estradiol + Norethindrone
Acetate). Such a product has extensively tested in several human pharmacokinetic studies (Proceed. Int'l Symp. Control. Rel. Bioact. Mater., 25, CRS, Inc, poster # 5513, 5514 and Proceed. Int'l Symp. Control. Rel. Bioact. Mater., 26, CRS, Inc, poster #5160). Therefore, the comparative in vitro results allow us to consistently predict the in vivo plasmatic level profile for other active agents. Furthermore, preliminary bioavailability studies were carried out for several formulations containing the present invention. Combi Gel™ is a trademark comprising the invention claimed herein, that means the combination of penetration enhancers.
To further exemplify the invention herein describe, a sorting in groups of active drugs was made, describing in each case the most relevant in vitro and in vivo results that support the present invention. Tables and graphics illustrate the results obtained, furthermore, in vivo studies protocols and the corresponding results obtained are disclosed. Group A: Hormones
1) Combi Gel™ LN+E2:
A) In vitro permeation study comparing a E2 + LN hydroalcoholic gel without using the inventive means against an E2 + LN gel containing our invention (Combi Gel™
LN+E2).
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under non-occlusive conditions, at 35°C and 600 rpm of stirring speed. Prior to the beginning of the study, the skin pieces were mounted in the permeation cells and maintained at 35°C in contact with the receptor solution. After loading 50 mg of each formulation over the skin, at the indicated times, 1 ml of the receptor solution was withdrawn, and the receptor chamber was immediately refilled with fresh solution. Table I
In vitro flux of Estradiol (Slope of cumulative amount of permeated drug vs. time between 12 and 24 h.)
Mean +S.D.
Figure imgf000031_0001
(*) 0,06 % w/w of 17β Estradiol; 0,09 %> w/w of Levonorgestrel; with permeation enhancers system
Table II Estradiol in vitro permeation
Figure imgf000031_0002
(**) 0,06 % w/w of 17β Estradiol; 0,09 % w/w of Levonorgestrel; without permeation enhancers system
Table III
In vitro flux of Levonorgestrel (Slope of cumulative amount of permeated drug vs. time between 12 and 24 h.)
Mean ±S.D.
Figure imgf000032_0001
(*) 0,06 % w/w of 17β Estradiol; 0,09 % w/w of Levonorgestrel; with permeation enhancers system
(**) 0,06 %> w/w of 17β Estradiol; 0,09 %> w/w of Levonorgestrel; without permeation enhancers system
Table IV Levonorgestrel in vitro permeation
Figure imgf000032_0002
These results show an increment in the cumulative amount permeated of both actives when the invention is present in the formulation (about 2 or 3 times higher). In addition, a more sustained flux of drug can be observed for E2 in that case. This behavior can be attributed, as previously disclosed, to the synergistic combination of the permeation enhancers of the present invention.
Then, a preliminary bioavailability study was carried out in order to further confirm if therapeutic and sustained plasmatic levels of both actives are achieved.
B) BIOAVAILABILITY STUDY OF COMBI GEL ™ - LN (EXPERIMENTAL
PROTOCOL EC006)
Aim
The objective of the study was to evaluate the bioavailability of E2 and LN from an optimized Combi Gel® - LN, in 6 healthy postmenopausal female volunteers.
Study Design - Open labeled, bioavailability study.
- Study Drugs: E2 and LN
- Product in development: Combi Gel™ - LN Manufactured by: Permatec Laboratories SA. Lot.N0: LNEg002-01 (Example 43)
Pharmaceutical Dosage Form: Gel.
- Route: Transdermal
- Volunteers: A total of 6 healthy postmenopausal women were selected. All of them completed the study and were submitted to analysis. - Treatment: A single, daily 2.5 g of Combi Gel - LN application on the external face of the thighs (1.25 g on 400 sqcm of each thigh), during 6 days. - Biological sampling schedule: Venous blood samples were collected immediately prior to (basal value) and at 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 168 h after the first application of Combi Gel - LN - Analytical assay method: E2 and LN serum levels were assayed using radioimmunoassay.
Results
Table V
Serum Levels of Estradiol (pg/ml)
Figure imgf000034_0001
Table V I CO l\3 Serum Levels of Levonorgestrel (pg/ml)
Figure imgf000034_0002
The results herein disclosed clearly demonstrate that both active agents reached therapeutic and sustained plasmatic levels with only one daily application of the transdermal gel tested. 2) Combi GelΥM Testosterone: A) In vitro permeation study comparing a Testosterone hydroalcoholic gel without including the invention herein disclosed, against a Testosterone gel containing our invention (Combi Gel™ Testosterone): a combination of lauryl alcohol and diethylene glycol monoethyl ether. Two more examples were tested, one containing lauryl alcohol alone as permeation enhancer and the other containing Diethylene glycol monoethyl ether. All examples contains 1,25 % w/w of Testosterone.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under non-occlusive conditions, at 35°C and 600 rpm of stirring speed. Prior to the beginning of the study, the skin pieces were mounted in the permeation cells and maintained at 35°C in contact with the receptor solution. After loading 50 mg of each formulation over the skin, at the indicated times, 1 ml of the receptor solution was withdrawn, and the receptor chamber was immediately refilled with fresh solution.
Table VII
Figure imgf000036_0001
* (Slope of cumulative amount of permeated drug vs. time between 12 and 24 h.)
Example 1 contains Lauryl alcohol and Diethylene glycol monoethyl ether as permeation enhancers system.
Example 2 contains Diethylene glycol monoethyl ether alone.
Example 3 contains Lauryl alcohol alone
Example 9 contains no permeation enhancers
Table VIII
Figure imgf000036_0002
B) BIOAVAILABILITY STUDY OF COMBI GEL ™ - TESTOSTERONE
(EXPERIMENTAL PROTOCOL EC009)
Aim
The objective of the study was to evaluate the bioavailabihty of Testosterone from an optimized Combi Gel™ TESTOSTERONE in 8 hypogonadal volunteers.
Study Design
- Open labeled, bioavailabihty study.
- Drug studied: Testosterone
- Product in development: Combi Gel™- Testosterone
- Lot N° : Tg021-02 (same formulation than Example 8) -Manufactured by: Permatec Laboratorios SA. -Pharmaceutical Dosage Form: Gel. Testosterone 1,25 % w/w
- Route: Transdermal
- Volunteers: A total of 8 hypogonadal volunteers were selected. 7 of them completed the study and were submitted to analysis.
- Treatment: A single, daily 5.0 g of Combi Gel'"- Testosterone application on both shoulders and arms (2.50 g on each shoulder and arm), during 12 days. Biological sampling schedule: Blood sampling was made each 24 h. During day 1 and 12 a stressed sampling was made.
Analytical assay method: Testosterone serum concentration was determined using
RIA.
Results
Table IX
Serum Levels of Testosterone (ng/ml)
Figure imgf000037_0001
The steady state was reached during the 2nd day. Testosterone steady state were maintained between 48 and 288 h. Mean testosterone serum level within this period was 3.73 +/-1.70ng/mL.
Table X Pharmacokinetic parameters of testosterone, after repeated administration of a transdermal gel containing testosterone in 7 healthy volunteers (Mean values)
Figure imgf000037_0002
Calculation made on the last 24 h values of the study ) Combi Gel™ Testosterone/Estradiol:
A) In order to further evaluate the feasibility of a combination gel containing Testosterone + Estradiol containing the invention herein disclosed, an in vitro permeation study comparing a Combi Gel Testosterone + Estradiol against a Norethindrone Acetate + Estradiol composition disclosed in the US Patent 5,891,462 was carried out.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under non-occlusive conditions, at 35°C and 600 m of stirring speed. Prior to the beginning of the study, the skin pieces were mounted in the permeation cells and maintained at 35°C in contact with the receptor solution. After loading 50 mg of each formulation over the skin, at the indicated times, 1 ml of the receptor solution was withdrawn, and the receptor chamber was immediately refilled with fresh solution.
Table XI
In vitro flux of Estradiol
(Slope of cumulative amount of permeated drug vs. time between 6 and 24 h.)
Mean ±S.D.
Figure imgf000039_0001
(*) Contains 0,06 % w/w of 17β Estradiol.
Table XII Estradiol in vitro permeation
Figure imgf000039_0002
n.a. means not available
Table XIII
In vitro flux of Testosterone and Norethindrone Acetate
(Slope of cumulative amount of permeated drug vs. time between 6 and 24 h.)
Mean ±S.D.
Figure imgf000040_0001
(1) Contains 1,20 %> w/w of Norethindrone Acetate.
(2) Contains 0,60 % w/w of Testosterone
(3) Contains 0,18 % w/w of Testosterone
Table XIV Testosterone and Norethindrone Acetate in vitro permeation
Figure imgf000040_0002
The formulation containing Testosterone 0,60 %w/w and Estradiol 0,060 %w/w (Example 17) was selected for its evaluation in a preliminary bioavailabihty study.
B) BIOAVAILABILITY STUDY OF COMBI GEL ™ - TESTOSTERONE +
ESTRADIOL (EXPERIMENTAL PROTOCOL EC012)
Aim
The objective of the study was to evaluate the bioavailability of Testosterone and
Estradiol from an optimized Combi Gel™ TESTOSTERONE + ESTRADIOL in 6 healthy postmenopausal women volunteers. Study Design
- Open labeled, bioavailabihty study.
- Drugs Studied: Testosterone + Estradiol
- Product in development: Combi Gel™- Testosterone + Estradiol - Manufactured by: Permatec Laboratorios SA
- Lot N°: Teg007-02, same composition as Example 17 (TEg005-01)
- Pharmaceutical Dosage Form: Gel. Testosterone 0,60 % w/w + Estradiol 0,060 % w/w.
- Route: Transdermal - Volunteers: A total of 6 healthy postmenopausal women were selected. All of them completed the study and were submitted to analysis.
- Treatment: A single, daily 5.0 g of Combi Gel™ - Testosterone + Estradiol application on shoulders and arms (2.50 g on each shoulder and arm), during 6 days.
- Biological sampling schedule: Venous blood samples were collected immediately prior to (basal value) and at 24, 48, 72, 96, 120, 144, 146, 150, 156, 168 h after the first application of Combi Gel TestoE2.
- Analytical assay method: E2 serum levels were assayed using immunofluorescence and Testosterone serum levels were assayed using radioimmunoassay.
Results
Table XV
Serum Levels of Estradiol (pg/ml)
Figure imgf000042_0001
Table XVI o Serum Levels of Testosterone (ng/ml)
Figure imgf000042_0002
Both active agents achieved sustained and controlled plasmatic levels utilizing the invention means herein claimed. Although, the plasmatic levels of both active agents are near to the upper limit of the therapeutic window. Therefore, less dosage or less concentration of the active drugs would be tested in future clinical studies. 4) Combi Gel™Levonorgestrel/Ethynil Estradiol
A) In order to further evaluate the feasibility of a combination gel containing L- Norgestrel + Ethynil Estradiol and the invention herein disclosed, an in vitro permeation study comparing two Combi Gel L-Norgestrel + Ethynil Estradiol (with different content in Ethynil Estradiol) against a Combi Gel Norethindrone Acetate + Estradiol already disclosed in the US Patent 5,891,462 was carried out.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % W/W polyoxyethylene 20 oleyl ether (Oleth 20). The experiments were conducted under occlusive conditions, at 35°C and 600 φm of stirring speed. Prior to the beginning of the study, the skin pieces were mounted in the permeation cells and maintained at 35°C in contact with the receptor solution. After loading 400 mg of each formulation over the skin, at the indicated times, 1 ml of the receptor solution was withdrawn, and the receptor chamber was immediately refilled with fresh solution. Table XVII
In vitro flux of Estrogens (Slope of cumulative amount of permeated drug vs. time between 16 and 32 h.)
Mean ±S.D.
Figure imgf000043_0001
(1) Contains 0,06 % w/w of Estradiol
(2) Contains 0,06 % w/w of Ethynil Estradiol
(3) Contains 0,09 % w/w of Ethynil Estradiol Table XVIII Estrogens in vitro permeation
Figure imgf000044_0001
Table XIX
In vitro flux of Progestagens
(Slope of cumulative amount of permeated drug vs. time between 16 and 32 h.)
Mean ±S.D.
Figure imgf000044_0002
(4) Contains 1,20 %> w/w of Norethindrone Acetate
(5) Contains 0,09 % w/w of Levonorgestrel
(6) Contains 0,09 % w/w of Levonorgestrel
Table XX Progestagens in vitro permeation
Figure imgf000045_0001
These results shown a similar behavior and permeation profile when compared with other examples previously described containing Levonorgestrel and Estradiol, then, we can conclude that an enhancement factor was achieved also in the present examples. Also, these results suggests that a combination Ethynil Estradiol + Levonorgestrel
Gel is considered feasible, since a prediction of in vivo fluxes for both actives when it was compared with Combi Gel NETA + E2 (example 34) concluded to be very close to the recommended daily doses. That means, about 50 μg/day for Ethynil Estradiol and 200- 300 μg/day for Levonorgestrel. Combi Gel™ Progesterone
A) In order to further evaluate the feasibility of a gel containing natural Progesterone and utilizing the invention herein disclosed, an in vitro permeation study comparing two different examples of Combi Gel Progesterone (with different content in Progesterone) against a cream containing 30 mg/g of natural Progesterone (Pro- Gest® commercialized by Emerita) was carried out.
Pro-Gest® is a commercially available cream containing 30 mg/g of original natural Progesterone. Pro-Gest® has been claimed as a product to help maintain balance in woman's lives and keep them feeling in harmony with their bodies. There are publications of two independent clinical studies showing the results of the effect of Pro-Gest® percutaneous progesterone body cream on postmenopausal women
("Percutaneous absoφtion of progesterone in postmenopausal women treated with transdermal estrogen", Kennneth A., Buπy MD, Phillip E., Patton, MD., and Kent Hermsmeyer PhD, Portland, Oregon. "Transdermal Progesterone Cream for Vasomotor Symptoms and Postmenopausal Bone Loss", Helene B. Leonetti, MD, Santo Longo, MD, and James N. Anasti, MD.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under non-occlusive conditions, at 35°C and 600 φm of stirring speed. Prior to the beginning of the study, the skin pieces were mounted in the permeation cells and maintained at 35°C in contact with the receptor solution. After loading 50 mg of each formulation over the skin, at the indicated times, 1 ml of the receptor solution was withdrawn, and the receptor chamber was immediately refilled with fresh solution.
Table XXI
In vitro flux of Progesterone
(Slope of cumulative amount of permeated drug vs. time between 6 and 24 h.)
Mean ±S.D.
Figure imgf000046_0001
(1) Contains 1,0 % w/w of Natural Progesterone.
(2) Contains 2,0 % w/w of Natural Progesterone.
(3) Contains 3,0 % w/w of Natural Progesterone.
Table XXII
Figure imgf000047_0001
According to these results, a Combi Gel™ Progesterone using the invention herein described is considered highly feasible. Group B: BENZODIAZEPINES
6) Combi Gel™ Alprazolam
I. Alprazolam Transdermal System
In vitro studies were performed in order to evaluate the effect of permeation enhancers on alprazolam permeation profile. After that, a Combi Gel Alprazolam containing 1,0 % w/w of Alprazolam was compared in an in vitro study against
Combi Gel NETA already described in order to theoretically evaluate the feasibility of the Alprazolam gel .
Finally, a bioavailabihty study was performed.
A) In vitro results:
The following tables and graphic intend to illustrate the behavior of Alprazolam in terms of permeability when some of the permeation enhancers herein disclosed are present in a propylene glycol solution containing 1,0 %> w/w of the active drug.
Table XXIII
Figure imgf000047_0002
LA: contains Laurie Acid OA: contains Oleic Acid OAL: contains Oleyl Alcohol LAOL: contains Lauryl Alcohol It is clearly advisable the effect of the addition of the permeation enhancers to a solution containing Alprazolam as active agent. With the extremely low cumulative amount value obtained with the solution without containing permeation enhancers, one can expect very low rate of permeability for this active drug, nevertheless, the addition of the permeation enhancers clearly increase many times the flux of active drug permeated.
B) BIOAVAILABILITY STUDY OF COMBI GEL ™ ALPRAZOLAM (EXPERIMENTAL PROTOCOL EC008) Aim The objective of the study was to evaluate the bioavailabihty of alprazolam after daily application of an optimized Combi Gel Alprazolam, during 7 days in 4 adult healthy volunteers. Study Design
- Open labeled, bioavailability study. - Drug Studied: Alprazolam
- Product in development: Combi Gel™ Alprazolam Manufactured by: Permatec Laboratorios SA. Lot.N°: Alg004-03 (same formulation as Example 23) Pharmaceutical Dosage Form: Gel. - Route: Transdermal
- Volunteers: A total of 4 healthy volunteers were selected. All of them completed the study.
- Treatment: A single daily dose of 2.0 g of Combi Gel® Alprazolam was applied on the shoulders (one gram on a 400 cm2 area of each shoulder) during 7 days. - Biological sampling schedule: Venous blood samples were collected immediately prior to (basal value) and at 1, 3, 6, 12, 24, 72, 73, 75, 78, 84, 96, 144, 145, 147, 150, 156 y 168 h after the first application of gel.
- Analytical assay method: Alprazolam plasma levels were assayed using HPLC. Table XXIV
Plasma Levels of Alprazolam (ng/ml)
-J
Figure imgf000049_0001
These results show that Combi Gel Alprazolam reached the therapeutic plasmatic levels (between 2-10 ng/ml) described in the literature for a single oral dose of 1 mg
Alprazolam (J. Clin. Pharmacol. 1989;29:543-549, Pharmacokinetics and
Pharamacodynamics of Alprazolam Following Single and Multiple Oral Doses of a
Sustained-Release Formulation). Furthermore, utilizing the invention means herein claimed, it is possible to achieve sustained plasmatic levels avoiding "peaks and valleys" with only one daily application of Combi Gel Alprazolam.
II. Alprazolam Transmucosal (Buccal) System
A) An In vitro permeation study was performed in order to evaluate the influence of the addition of the invention means, on the active drug permeation profile. A Combi
Gel Alprazolam able to be administered by the buccal mucosa, was tested. A Combi
Gel Alprazolam containing 0,5 %> w/w of the active drug and the invention herein described was compared against a 0,5 %> w/w Alprazolam Gel without using the invention.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Hamster cheek pouch was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under occlusive conditions, at 37°C and 600 φm of stirring speed.
200 mg of each formulation were loaded per cell. One sample of receptor solution was taken at 0.5 h and analyzed for alprazolam content.
Results
Table XXV Alprazolam in vitro transmucosal permeation
Figure imgf000050_0001
(1) 0,5%ow/w Alprazolam with the invention
(2) 0,5%w/w Alprazolam without the invention B) An In vivo Comparative bioavailabihty study in rabbits was also performed (EA
005/99)
Study Design
An Alprazolam Buccal Gel developed by Permatec Lab. SA was compared against one marketed alprazolam pill. In the first period of the study the animals (3 adult female rabbits, weighing around 2 Kg) were given one pill containing 1,0 mg of alprazolam. In the second period the same animals received one dose of 200 mg of
Alprazolam Buccal Gel (containing 1,0 mg of Alprazolam). Blood samples were taken at the time points indicated in the table and graphic. Alprazolam was analyzed by HPLC.
Results
Table XXVI
Alprazolam pill
Figure imgf000051_0001
N.A. not available
Table XXVII Alprazolam Gel
Figure imgf000052_0001
These results clearly show that the invention herein disclosed included in a buccal gel, promotes higher serum levels of Alprazolam than a pill administered perorally.
As demonstrated by all the results presented before, comparatives in vitro study against reference products (i.e. Combi Gel NET A) allow us to predict the feasibility of the intended project.
For that reason, the groups of drugs described below, were evaluated on in vitro tests against a reference product and concluded to be feasible to be administered by transdermal or transmucosal route using the invention herein described.
Group C: ANTIHYPOTHYROID 7) Combi Gel™ L-Tiroxine
A) An In vitro permeation study was performed in order to evaluate the influence of the addition of the invention means, on L-Tiroxine permeation profile. Thus, solutions of the active drug, with and without the addition of the invention means, were in vitro tested.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under occlusive conditions, at 37°C and 600 φm of stirring speed. 2 ml of each formulation was loaded per cell. One sample of receptor solution was taken at different time points.
Results
Table XXVIII
In vitro flux of L-Tiroxine (Slope of cumulative amount of permeated drug vs. time between 6 and 24 h.)
Mean ±S.D.
Figure imgf000054_0001
(1) Contains 0,40 % w/w of L-Tiroxine with the invention.
(2) Contains 0,40 %> w/w of L-Tiroxine without the invention.
Table XXIX L-Tiroxine in vitro permeation
Figure imgf000054_0002
These results clearly shown a significant increment in the cumulative amount permeated of L-Tiroxine when the invention is present in the formulation (about 24 times at 24 hours).
Then, we can conclude that a formulation to administer the antihypotiroid drug at an adequate permeation rate could be achieved by using the present invention. Group D: ANTIHYPERTENSIVES/CALCIUM CHANNEL BLOCKERS
8) Combi Gel™ Amlodipine
A) In vitro permeation studies were performed in order to evaluate the influence of the addition of the invention means, on Amlodipine Besylate and Amlodipine (base form) permeation profile. Thus, solutions of the active drugs, with and without the addition of the invention means, were in vitro tested.
Study conditions: Franz Vertical Diffusion Cells (Hanson Research Inc.); Pre-shaved abdominal Guinea pig skin was used as experimental model. The receptor solution was 2 % w/w polyoxyethylene 20 oleyl ether (Oleth 20), PBS lOmM, pH 7.4. The experiments were conducted under occlusive conditions, at 35°C and 600 φm of stirring speed. 3 ml of each formulation was loaded per cell. One sample of receptor solution was taken at different time points. Results
Table XXX
Amlodipine and Amlodipine Besylate in vitro permeation
Cumulative Amounts (μg/cm2), Mean±SD
Figure imgf000055_0001
(1) Contains 1,00% w/w of Amlodipine Besylate with the additon of the invention means
(2) Contains 1,00%) w/w of Amlodipine Besylate without the invention means
(3) Contains 1,00%> w/w of Amlodipine with addition of the invention means
(4) Contains 1,00%> w/w of Amlodipine without the invention means
These results clearly shown a very significant increment in the cumulative amount permeated of both Amlodipine forms (base and Besylate) when the invention is present in the formulation (about 85 times for the Besylate and more than 450 times for the base). The enhancement effect is clearly greater for the base form. Then, we can conclude that a formulation to administer the antihypertensive agent at an adequate permeation rate could be achieved by using the present invention.

Claims

1. Pharmaceutical composition suitable for the transdermal or transmucosal administration of one or more active agents, in form of a gel or a solution, comprising as a permeation enhancers a combination of: a) saturated fatty alcohol of formula CH3-(CH2)n-CH2OH or saturated fatty acid CH3- (CH2)n-CH2COOH wherein n is an integer number 8 ÷ 22, preferably 8 ÷ 12, most preferably 10, or unsaturated fatty alcohol or fatty acid of formula: CH3(CnH2(n-i))-OH or CH3(CnH2tn-i))-COOH wherein n is an integer number 8 ÷ 22, b) a ternary vehicle or carrier consisting of a Ci ÷ C4 alkanol, a polyalcohol in particular propylenglycol and water, c) optionally also a monoalkylether of diethylenglycol.
2. Pharmaceutical composition according to claim 1 wherein the active agents are comprised in the class of estrogen hormons.
3. Pharmaceutical composition according to claim 1 wherein the active agents are comprised in the class of androgen hormons.
4. Pharmaceutical composition according to claim 1 wherein the active agents are sedatives and anxyolitics of the type benzodiazepine or amides such as Butoctamide, diethylbromoacetamide, isovaleryl-diethylamide.
5. Pharmaceutical composition according to claim 1 wherein the active agents are antihypothyroid honnones.
6. Pharmaceutical composition according to claim 1 wherein the active agents are antihypertensive.
7. Pharmaceutical composition according to claim 1 wherein the active agents are calcium regulators, such as Calcitonin, Calcifediol, parathyroid hormone.
8. Pharmaceutical composition according to claim 1, wherein:
- the component a) is in amount comprised between 0.1% and 20% by weight (preferably 0.2 ÷ 3%),
- the component b) comprises 5% ÷ 75% by weight of alkanol on the whole composition and 0.5% ÷ 50% of a glycol,
- the component c) is in amount up to 40%o by weight (preferably 2 ÷ 8%),
9. Pharmaceutical composition according to claim 1 or 2 in form of gel, comprising, as gelling agent:
- a polyacrylic acid such as carbopol
- a cellulose derivative such as hydroxypropylmethylcellulose, carboxymethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose
- polyvinylpyrrolidone
- polyoxyethylene/polyoxypropylene copolymers
- polyvinylalcohol
- natural gums, alginates, pectins.
10. Pharmaceutical composition according to claim 3 wherein the amount of gelling agent is comprised between 0.2 and 30% by weight.
PCT/EP2001/009007 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels WO2002011768A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
NZ524423A NZ524423A (en) 2000-08-03 2001-08-03 A composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
AU2001282064A AU2001282064B2 (en) 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
JP2002517102A JP2004505931A (en) 2000-08-03 2001-08-03 Novel compositions for transdermal and / or transmucosal administration of active compounds ensuring adequate therapeutic levels
ES01960619T ES2283425T3 (en) 2000-08-03 2001-08-03 NEW COMPOSITION FOR THE TRANSDERMAL AND / OR TRANSMUCTIVE ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURE ADEQUATE THERAPEUTIC LEVELS.
KR1020037001526A KR100856523B1 (en) 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
AU8206401A AU8206401A (en) 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US10/343,570 US7214381B2 (en) 2000-08-03 2001-08-03 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
CA2418135A CA2418135C (en) 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
EP01960619A EP1307232B1 (en) 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
DE60127134T DE60127134T2 (en) 2000-08-03 2001-08-03 NEW COMPOSITION FOR TRANSDERMAL AND / OR TRANSMUCOSAL ACTIVE INGREDIENT USE WITH APPROPRIATE THERAPEUTIC MIRROR
US10/798,161 US7198801B2 (en) 2000-08-03 2004-03-10 Formulations for transdermal or transmucosal application
US11/634,005 US7404965B2 (en) 2000-08-03 2006-12-04 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US11/693,988 US7470433B2 (en) 2000-08-03 2007-03-30 Formulations for transdermal or transmucosal application
US11/755,923 US20070225379A1 (en) 2001-08-03 2007-05-31 Transdermal delivery of systemically active central nervous system drugs
US12/614,216 US8980290B2 (en) 2000-08-03 2009-11-06 Transdermal compositions for anticholinergic agents
US13/044,447 US20110195114A1 (en) 2000-08-03 2011-03-09 Transdermal delivery systems for active agents
US13/106,715 US20110245215A1 (en) 2000-08-03 2011-05-12 Transdermal delivery systems for active agents
US13/566,900 US8652491B2 (en) 2000-08-03 2012-08-03 Transdermal compositions for anticholinergic agents
US14/489,252 US20150005337A1 (en) 2000-08-03 2014-09-17 Transdermal Delivery Of Systemically Active Central Nervous System Drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP00/07533 2000-08-03
EP0007533 2000-08-03

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/343,570 A-371-Of-International US7214381B2 (en) 2000-08-03 2001-08-03 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US10343570 A-371-Of-International 2001-08-03
US10/798,161 Continuation-In-Part US7198801B2 (en) 2000-08-03 2004-03-10 Formulations for transdermal or transmucosal application
US11/634,005 Continuation US7404965B2 (en) 2000-08-03 2006-12-04 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels

Publications (1)

Publication Number Publication Date
WO2002011768A1 true WO2002011768A1 (en) 2002-02-14

Family

ID=8164048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009007 WO2002011768A1 (en) 2000-08-03 2001-08-03 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels

Country Status (12)

Country Link
US (2) US7214381B2 (en)
EP (4) EP1323431B1 (en)
JP (1) JP2004505931A (en)
KR (1) KR100856523B1 (en)
AR (1) AR030312A1 (en)
AT (3) ATE355854T1 (en)
AU (2) AU2001282064B2 (en)
CA (1) CA2418135C (en)
DE (3) DE60143360D1 (en)
ES (2) ES2283665T3 (en)
NZ (1) NZ524423A (en)
WO (1) WO2002011768A1 (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051421A2 (en) * 2000-12-22 2002-07-04 Dr. August Wolff Gmbh & Co. Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
WO2005027911A1 (en) * 2003-09-22 2005-03-31 Stephen Mamchur Hormone concentrate pharmaceutical compositon
EP1648406A2 (en) * 2003-03-11 2006-04-26 Antares Pharma IPL AG Uses and formulations for transdermal or transmucosal application of active agents
JP2007508261A (en) * 2003-10-10 2007-04-05 アンタレス ファルマ イーペーエル アクチェンゲゼルシャフト Transdermal pharmaceutical formulation to minimize skin residue
WO2007128923A2 (en) * 2006-05-05 2007-11-15 Anteis Sa Method for the preparation of a biocompatible gel with controlled release of one or more active ingredients with low solubility in water, gels thus obtained and their use
JP2007533604A (en) * 2003-08-08 2007-11-22 ミファルム ソシエタ ペル アチオニ Bioadhesive gel based on hydroxyethylcellulose
WO2008027395A2 (en) * 2006-08-28 2008-03-06 Jazz Pharmaceuticals, Inc. Pharmaceutical compositions of benzodiazepines and methods of use thereof
US20080220066A1 (en) * 2005-09-02 2008-09-11 Henderson Morley Plc Anti-Viral Topical Gel Formulations Containing a Diuretic Such as Furosemide and/or a Cardiac Glycoside Such as Digoxin
KR100866715B1 (en) * 2000-08-30 2008-11-03 유니메드 파마슈티칼스, 엘엘씨 Pharmaceutical composition and method for treating hypogonadism
US7611727B2 (en) 2003-02-20 2009-11-03 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration
WO2010105842A2 (en) 2009-03-19 2010-09-23 Bubbles And Beyond Gmbh Preparation for external application
EP2243483A1 (en) * 2009-04-21 2010-10-27 Bennie Rabin Amlodipine salt compositions for topical application
US7863311B2 (en) 2004-11-05 2011-01-04 Orion Corporation Transmucosal veterinary composition comprising detomidine
WO2011070318A2 (en) 2009-12-11 2011-06-16 Reckitt Benckiser Healthcare International Limited Topical formulation
US8338400B2 (en) 2005-05-27 2012-12-25 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8647665B2 (en) 2006-04-21 2014-02-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8652491B2 (en) 2000-08-03 2014-02-18 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2015199526A1 (en) * 2014-06-25 2015-12-30 Universidad Nacional Autónoma de México Transdermal patchwith chitosan and poloxamer
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10166205B2 (en) 2013-01-31 2019-01-01 Sebela International Bermuda Limited Topical compositions and methods for making and using same
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323431B1 (en) * 2000-08-03 2010-10-27 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
ES2237298B1 (en) * 2003-07-16 2006-11-01 Italfarmaco, S.A. SEMISOLID MUCOADHESIVE FORMULATIONS.
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
ES2265239B1 (en) * 2004-09-23 2008-02-01 Laboratorio Reig Jofre, S.A. PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION.
US7592021B2 (en) * 2004-10-02 2009-09-22 Sri International Bioadhesive delivery system for transmucosal delivery of beneficial agents
US20070082048A1 (en) * 2005-06-08 2007-04-12 Ronald Warner Sleep aid formulations
CN101237889A (en) * 2005-06-16 2008-08-06 沃纳奇尔科特公司 Estrogen compositions for vaginal administration
CN101237851B (en) * 2005-06-16 2013-09-18 沃纳奇尔科特有限责任公司 Estrogen compositions for vaginal administration
WO2006138735A2 (en) * 2005-06-16 2006-12-28 Warner Chilcott Company, Inc. Gel compositions for topical administration
DE102005050431A1 (en) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the administration of lipophilic and / or less skin-permeable active ingredients
WO2008012071A2 (en) * 2006-07-24 2008-01-31 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
ES2310968B1 (en) 2007-06-25 2010-02-08 Italfarmaco, S.A. USE OF ESTRIOL IN LOW DOSE.
AR068409A1 (en) * 2007-09-14 2009-11-18 Drugtech Corp PHARMACEUTICAL, TRANSDERMIC COMPOSITIONS WITHOUT ALCOHOL
AR068408A1 (en) * 2007-09-14 2009-11-18 Drugtech Corp SPRAYING OF TRANSDERMAL HORMONES
CL2008003507A1 (en) 2007-11-26 2009-11-27 Neuroderm Ltd Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system.
US8927537B2 (en) * 2007-12-21 2015-01-06 Nuvo Research Inc. Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs
ES2344673B1 (en) 2008-08-07 2011-05-03 Italfarmaco, S.A. USE OF ESTRIOL IN THE PREPARATION OF A PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH RISK OF POTOLOGIATUMORAL.
CN102176818A (en) * 2008-08-12 2011-09-07 诺华贝制药公司 Antimicrobial gel formulations
ES2344675B1 (en) 2008-12-19 2011-04-28 Italfarmaco, S.A. USE OF ESTRIOL IN THE PREPARATION OF A PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH RISK OF VARIUM VARCOLOGY.
US8470304B2 (en) 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
RS54993B1 (en) 2010-05-12 2016-11-30 Radius Health Inc Therapeutic regimens
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
AU2011329782A1 (en) 2010-11-18 2013-06-20 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (en) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp FORMULATIONS IN INTRANASAL GEL OF TESTOSTERONE IN DOSE OF LOWER POWER AND USE OF THE SAME FOR THE TREATMENT OF ANORGASMIA OR THE DISORDER OF HYPOACTIVE SEXUAL DESIRE
WO2014083432A2 (en) * 2012-11-14 2014-06-05 Trimel Biopharma Srl Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
EP3242659A4 (en) 2015-01-09 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
CN108135177B (en) 2015-04-29 2021-06-01 雷迪厄斯制药公司 Methods for treating cancer
WO2016187269A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
WO2017053594A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Compositions and methods of using the same for decontamination of skin
US20170368036A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
KR102322802B1 (en) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic form of RAD1901-2HCL
US9987207B1 (en) 2017-06-29 2018-06-05 L'oreal Foaming warming cleanser
EP3737374A4 (en) 2018-01-10 2021-09-29 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
CA3104395A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
EP3843729A4 (en) * 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. Novel compositions and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249397A2 (en) * 1986-06-13 1987-12-16 The Procter & Gamble Company Improved penetrating topical pharmaceutical compositions
US4952560A (en) * 1984-04-05 1990-08-28 Takeda Chemical Industries, Ltd. Ointment base
EP0672422A1 (en) * 1994-02-05 1995-09-20 Il-Dong Pharm. Co., Ltd. Antiinflammatory and analgesic transdermal gel
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
EP0811381A1 (en) * 1996-06-06 1997-12-10 Permatec N.V. A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
WO1999024041A1 (en) * 1997-11-10 1999-05-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US3143465A (en) 1961-06-19 1964-08-04 Wallace & Tiernan Inc Pharmaceutical preparations comprising phosphorus containing cation exchange resins having a basic drug adsorbed thereon; and treatment therewith
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
DE2350315C2 (en) 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmaceutical and cosmetic preparations for external use
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4082881A (en) 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4383993A (en) 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
US4315925A (en) 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
DE3333240A1 (en) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5783207A (en) 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
DE3522550A1 (en) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab SPRAYABLE PHARMACEUTICAL PREPARATION FOR TOPICAL APPLICATION
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5041439A (en) 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4808411A (en) 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5225189A (en) 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5059426A (en) 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4956171A (en) 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5232703A (en) 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
DE69007886T2 (en) 1989-07-21 1994-11-17 Izhak Blank Oestradiol containing agents and methods for topical use.
DE3937271A1 (en) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5602017A (en) 1990-04-10 1997-02-11 Kyowa Hakko Kogyo Co., Ltd. Cholesterol oxidase
US5371005A (en) 1990-04-10 1994-12-06 Kyowa Hakko Kogyo Co., Ltd. Cholesterol oxidase
AU648574B2 (en) 1990-07-20 1994-04-28 Tillotts Pharma Ag Products and processes for the treatment of the alimentary canal
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5238933A (en) 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5178879A (en) 1992-04-17 1993-01-12 Michael Adekunle Capsaicin gel
US5453279A (en) 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5900250A (en) 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
JP3655305B2 (en) 1992-11-23 2005-06-02 エスティー ローダー インコーポレーテッド Self-tanning cosmetic composition and method of using the same
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
AU7323794A (en) 1993-07-09 1995-02-06 Cygnus Therapeutic Systems Method and device for providing nicotine replacement therapy transdermally/transbuccally
DE4405898A1 (en) 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
FR2722102B1 (en) 1994-07-11 1996-08-23 Cird Galderma USE OF DEFORMABLE HOLLOW PARTICLES IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING FAT MATERIALS
US6309843B1 (en) 1994-10-25 2001-10-30 The Curators Of The University Of Missouri Glycoprotein for use in determining endometrial receptivity
US5831035A (en) 1994-10-25 1998-11-03 Curators Of The University Of Missouri Antibody against human endometrial stromal cell glycoprotein
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US6124355A (en) 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5922349A (en) 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
FR2739558B1 (en) 1995-10-05 1997-11-28 Innothera Lab Sa UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
DE19548332A1 (en) 1995-12-22 1997-07-10 Rotta Res Bv hormone patches
EP0785212A1 (en) 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US5814659A (en) 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition
DE19619045C1 (en) 1996-05-02 1997-11-13 Jenapharm Gmbh Use of combination products for the treatment of hypogonadal men and men with pituitary disorders
GB9610862D0 (en) 1996-05-23 1996-07-31 Evans Brian K Pharmaceutical products
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
HU228855B1 (en) 1997-03-12 2013-06-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
US6426078B1 (en) 1997-03-17 2002-07-30 Roche Vitamins Inc. Oil in water microemulsion
DE69819721T2 (en) 1997-06-13 2004-09-23 Cydex Inc., Overland Park COMPOSITION WITH INCREASED STORAGE STABILITY CONTAINING CYCLODEXTRIN AND ACTIVE SUBSTANCES OR SUBSTANCES PREPARED IN WATER-INSOLUBLE COMPONENTS
US6034079A (en) 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
DE19827732A1 (en) 1998-06-22 1999-12-23 Rottapharm Bv Transdermal patch useful for hormone replacement therapy used for treatment of menopausal symptoms
AU4972599A (en) 1998-07-07 2000-01-24 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913732A1 (en) * 1999-03-26 2000-09-28 Lohmann Therapie Syst Lts Nicotine TTS with the addition of monoterpene ketones
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1202736B1 (en) 1999-07-28 2008-09-17 The Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2798065B1 (en) * 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris USE OF NICOTINE OR DERIVATIVES THEREOF IN A MEDICAMENT FOR THE TREATMENT OF NEUROLOGICAL DISEASES, ESPECIALLY PARKINSON'S DISEASE
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6432446B2 (en) 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
EP2322170A1 (en) * 2000-04-26 2011-05-18 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EP1323431B1 (en) * 2000-08-03 2010-10-27 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US6545046B2 (en) * 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
EP1231158A1 (en) * 2001-02-12 2002-08-14 Hellermann Tyton GmbH Strip of interconnected locking pieces for tightening straps and tool for their application
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
MXPA04006017A (en) * 2001-12-20 2005-06-08 Femmepharma Inc Vaginal delivery of drugs.
US6951846B2 (en) * 2002-03-07 2005-10-04 The United States Of America As Represented By The Secretary Of The Army Artemisinins with improved stability and bioavailability for therapeutic drug development and application
US6586449B1 (en) * 2002-05-28 2003-07-01 Cambrex Charles City, Inc. Nicotine-containing, controlled release composition and method
US6889875B2 (en) * 2002-06-04 2005-05-10 Cellegy Pharmaceuticals, Inc. Taper well meter dose pump
DE10253216A1 (en) * 2002-11-15 2004-05-27 Cognis Deutschland Gmbh & Co. Kg Use of low molecular weight protein hydrolyzates in washing and cleaning agents
US6995265B2 (en) * 2003-08-26 2006-02-07 North Carolina State University Synthesis of nicotine derivatives from nicotine
MXPA06003316A (en) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952560A (en) * 1984-04-05 1990-08-28 Takeda Chemical Industries, Ltd. Ointment base
EP0249397A2 (en) * 1986-06-13 1987-12-16 The Procter & Gamble Company Improved penetrating topical pharmaceutical compositions
EP0672422A1 (en) * 1994-02-05 1995-09-20 Il-Dong Pharm. Co., Ltd. Antiinflammatory and analgesic transdermal gel
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
EP0811381A1 (en) * 1996-06-06 1997-12-10 Permatec N.V. A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
WO1999024041A1 (en) * 1997-11-10 1999-05-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US8652491B2 (en) 2000-08-03 2014-02-18 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
KR100866715B1 (en) * 2000-08-30 2008-11-03 유니메드 파마슈티칼스, 엘엘씨 Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
EP2281553B1 (en) * 2000-08-30 2020-12-02 Unimed Pharmaceuticals, LLC Pharmaceutical composition and method for treating hypogonadism
EP2070517A3 (en) * 2000-08-30 2009-07-29 Unimed Pharmaceuticals Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002051421A3 (en) * 2000-12-22 2002-11-07 August Wolff Gmbh & Co Dr Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
WO2002051421A2 (en) * 2000-12-22 2002-07-04 Dr. August Wolff Gmbh & Co. Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
US7611727B2 (en) 2003-02-20 2009-11-03 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration
EP1648406A4 (en) * 2003-03-11 2012-03-21 Antares Pharma Ipl Ag Uses and formulations for transdermal or transmucosal application of active agents
EP1648406A2 (en) * 2003-03-11 2006-04-26 Antares Pharma IPL AG Uses and formulations for transdermal or transmucosal application of active agents
US7858607B2 (en) 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
JP2007533604A (en) * 2003-08-08 2007-11-22 ミファルム ソシエタ ペル アチオニ Bioadhesive gel based on hydroxyethylcellulose
JP4855935B2 (en) * 2003-08-08 2012-01-18 ミテック−イデア ソシエタ ア レスポンサビリタ リミタータ Bioadhesive gel based on hydroxyethylcellulose
WO2005027911A1 (en) * 2003-09-22 2005-03-31 Stephen Mamchur Hormone concentrate pharmaceutical compositon
JP2007508261A (en) * 2003-10-10 2007-04-05 アンタレス ファルマ イーペーエル アクチェンゲゼルシャフト Transdermal pharmaceutical formulation to minimize skin residue
US8980309B2 (en) * 2003-10-10 2015-03-17 Antares Pharma Ipl Ag Transdermal testosterone formulation for minimizing skin residues
US20110257141A1 (en) * 2003-10-10 2011-10-20 Antares Pharma, Ipl, Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8309591B2 (en) 2004-11-05 2012-11-13 Orion Corporation Transmucosal veterinary composition comprising detomidine
US7863311B2 (en) 2004-11-05 2011-01-04 Orion Corporation Transmucosal veterinary composition comprising detomidine
US8338400B2 (en) 2005-05-27 2012-12-25 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20080220066A1 (en) * 2005-09-02 2008-09-11 Henderson Morley Plc Anti-Viral Topical Gel Formulations Containing a Diuretic Such as Furosemide and/or a Cardiac Glycoside Such as Digoxin
US8647665B2 (en) 2006-04-21 2014-02-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2007128923A2 (en) * 2006-05-05 2007-11-15 Anteis Sa Method for the preparation of a biocompatible gel with controlled release of one or more active ingredients with low solubility in water, gels thus obtained and their use
WO2007128923A3 (en) * 2006-05-05 2008-05-02 Anteis Sa Method for the preparation of a biocompatible gel with controlled release of one or more active ingredients with low solubility in water, gels thus obtained and their use
US8716279B2 (en) 2006-08-28 2014-05-06 Jazz Pharmaceuticals, Inc. Pharmaceutical compositions of clonazepam and method of use thereof
WO2008027395A3 (en) * 2006-08-28 2008-04-17 Jazz Pharmaceuticals Pharmaceutical compositions of benzodiazepines and methods of use thereof
US8609651B2 (en) 2006-08-28 2013-12-17 Jazz Pharmaceuticals, Inc. Pharmaceutical compositions of benzodiazepines and method of use thereof
WO2008027395A2 (en) * 2006-08-28 2008-03-06 Jazz Pharmaceuticals, Inc. Pharmaceutical compositions of benzodiazepines and methods of use thereof
WO2010105842A2 (en) 2009-03-19 2010-09-23 Bubbles And Beyond Gmbh Preparation for external application
DE102009013469A1 (en) 2009-03-19 2010-12-09 Bubbles And Beyond Gmbh Preparation for external use
EP2243483A1 (en) * 2009-04-21 2010-10-27 Bennie Rabin Amlodipine salt compositions for topical application
US11040043B2 (en) 2009-10-27 2021-06-22 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2011070318A2 (en) 2009-12-11 2011-06-16 Reckitt Benckiser Healthcare International Limited Topical formulation
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846649B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846648B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US10729667B2 (en) 2013-01-31 2020-08-04 Sebela Ireland Limited Topical compositions and methods for making and using same
US10695303B2 (en) 2013-01-31 2020-06-30 Sebela Ireland Limited Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US10166206B2 (en) 2013-01-31 2019-01-01 Sebela International Bermuda Limited Topical compositions and methods for making and using same
US10166205B2 (en) 2013-01-31 2019-01-01 Sebela International Bermuda Limited Topical compositions and methods for making and using same
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
WO2015199526A1 (en) * 2014-06-25 2015-12-30 Universidad Nacional Autónoma de México Transdermal patchwith chitosan and poloxamer
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Also Published As

Publication number Publication date
DE60127277T2 (en) 2007-11-29
EP1323431A2 (en) 2003-07-02
DE60127277D1 (en) 2007-04-26
DE60127134D1 (en) 2007-04-19
ES2283665T3 (en) 2007-11-01
US20030199426A1 (en) 2003-10-23
EP1307232A1 (en) 2003-05-07
JP2004505931A (en) 2004-02-26
US20070098775A1 (en) 2007-05-03
EP1323430B1 (en) 2007-03-14
ATE356636T1 (en) 2007-04-15
US7214381B2 (en) 2007-05-08
EP1323430A2 (en) 2003-07-02
EP1325752A2 (en) 2003-07-09
AR030312A1 (en) 2003-08-20
EP1325752A3 (en) 2003-08-06
CA2418135A1 (en) 2002-02-14
CA2418135C (en) 2011-09-20
EP1323431B1 (en) 2010-10-27
KR100856523B1 (en) 2008-09-04
ATE355854T1 (en) 2007-03-15
US7404965B2 (en) 2008-07-29
NZ524423A (en) 2004-04-30
ATE485837T1 (en) 2010-11-15
AU8206401A (en) 2002-02-18
EP1307232B1 (en) 2007-03-07
EP1323430A3 (en) 2003-08-06
EP1323431A3 (en) 2003-08-06
KR20030031568A (en) 2003-04-21
DE60127134T2 (en) 2007-11-08
ES2283425T3 (en) 2007-11-01
DE60143360D1 (en) 2010-12-09
AU2001282064B2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
US7214381B2 (en) Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
AU2001282064A1 (en) Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7470433B2 (en) Formulations for transdermal or transmucosal application
JP5619337B2 (en) Transdermal pharmaceutical formulation to minimize skin residue
US20150005337A1 (en) Transdermal Delivery Of Systemically Active Central Nervous System Drugs
JP5441966B2 (en) Uses and formulations for transdermal or transmucosal application of active agents
US7387788B1 (en) Pharmaceutical compositions of nicotine and methods of use thereof
US20050244522A1 (en) Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
EP1742664A1 (en) Permeation enhancing compositions for anticholinergic agents
LV13303B (en) Pharmaceutical composition
CN1997357A (en) Uses and formulations for transdermal or transmucosal application of active agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2418135

Country of ref document: CA

Ref document number: 1020037001526

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001960619

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001282064

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 524423

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020037001526

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001960619

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10343570

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 524423

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524423

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001960619

Country of ref document: EP